Introduction {#s1}
============

The kidney serves central functions in metabolic waste excretion, osmoregulation, and electrolyte homeostasis. Vertebrate kidney organogenesis is a dynamic process involving the generation of up to three distinct structures that originate from the intermediate mesoderm (IM) ([@bib54]). In mammals, a pronephros, mesonephros, and metanephros develop in succession. Of these structures, the pronephros and mesonephros both eventually disintegrate, leaving the metanephros as the adult kidney. In contrast, lower vertebrates such as fish and amphibians only form a pronephros and mesonephros, which are active during embryogenesis and larval stages, respectively, and the mesonephros subsequently serves as the adult organ ([@bib11]).

During the progression of vertebrate kidney ontogeny, composition of the basic renal functional unit, termed the nephron, remains largely similar across species ([@bib9]). Nephrons contain a renal corpuscle that filters the blood, a tubule that modifies the filtrate solution, and a collecting duct ([@bib53]). The tubule portion of the nephron is configured along its proximo-distal axis with specific groupings of cells, termed segments, which possess unique physiological roles in solute reabsorption and secretion. While the organization of proximal and distal nephron segments is broadly conserved ([@bib53]), the genetic and molecular mechanisms that regulate formation of each segment lineage have yet to be fully described ([@bib8]).

The zebrafish embryonic pronephros is a useful model to delineate the processes that regulate vertebrate nephron segmentation because it is anatomically simple, being comprised of only two nephrons ([@bib18]). Further, the transparent nature of zebrafish embryos, their *ex utero* development, and the ease at which large numbers can be obtained and managed, are all features that readily facilitate renal development and disease studies ([@bib49]; [@bib51]). The zebrafish pronephric tubule has four discrete tubule segments: a proximal convoluted tubule (PCT), proximal straight tubule (PST), distal early (DE), and distal late (DL) ([@bib63]) ([Figure 1A](#fig1){ref-type="fig"}). The proximal segments are homologous to the PCT and PST in mammals, while the distal segments are homologous to the mammalian thick ascending limb (TAL) and distal convoluted tubule (DCT), respectively ([@bib63]; [@bib61]).10.7554/eLife.17551.002Figure 1.A novel small molecule screen reveals that prostaglandins alter nephron patterning.(**A**) A diagram detailing the segmentation of the pronephros in relation to somites within the zebrafish embryo. Arrows indicate the blood filter, duct, and cloaca. (**B**) A schematic of the chemical genetic screen used for evaluating small molecules. Embryos were arrayed in 96-well plates and then exposed to drugs diluted in E3 medium from 60% epiboly to 24 hpf, where the embryos were then fixed and underwent WISH using a riboprobe cocktail to detect the P (*wt1b*), PCT (*slc20a1a*), and DE (*slc12a1*). Black and blue bars are used to illustrate changes between the WT embryo and an embryo with a patterning phenotype, respectively. (**C**) A pie graph and table denoting the number and percentage of small molecules hits from the chemical screen that expanded or restricted the P (blue and teal), PCT (green and purple) or DE (red and yellow). (**D**) WISH in 24 hpf stage embryos to detect the P (*wt1b*), PCT (*slc20a1a*), and DE (*slc12a1*) in WTs and those treated with 4-HPR, PGD~2~, PGA~1~, PGJ~2~, and PGB~2~. A black or blue bar was used to notate the segment change between the WT and drug treated embryos, respectively. Red scale bar, 70 µm. (**E**) Schematic showing example components of prostaglandin production and signaling. The precursor arachidonic acid (AA) interacts with either the Ptgs1 or Ptgs2a enzyme to generate an intermediate moiety, with the example here being PGH~2~. The intermediate interacts with a subsequent enzyme to produce the bioactive prostanoid molecule. Here, we depict the prostaglandin E synthase, Ptges, creating the bioactive prostaglandin PGE~2~ that can transduce signals through binding several G-protein coupled receptors such as Ptger2a and Ptger4a. Other receptors work with other bioactive prostaglandins. Indomethacin is a nonselective Cox (Ptgs1/Ptgs2a) inhibitor that prevents prostaglandin biosynthesis.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.002](10.7554/eLife.17551.002)10.7554/eLife.17551.003Figure 1---source data 1.Compilation of chemical screen phenotypic data.For each compound, the dosage tested is listed along with the known biological function and the effect on zebrafish when treated between 4 and 24 hpf. The scoring key of ± indicates segment expansion or reduction.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.003](10.7554/eLife.17551.003)

During zebrafish kidney development, renal progenitors arise rapidly from the IM and undergo a mesenchymal to epithelial transition (MET) to engender the tubule by 24 hr post fertilization (hpf) ([@bib41]; [@bib19]). Prior to this, the renal progenitors undergo complex segment lineage patterning events, beginning with their segregation into rostral and caudal subdomains, a process that is orchestrated by the morphogen retinoic acid (RA) which is locally secreted by the adjacent paraxial mesoderm (PM) ([@bib63]; [@bib62]). Modulating levels of RA affects the specification of renal progenitors, inducing proximal segment lineage formation over distal, which can be accentuated by the addition of exogenous all-trans RA, while distal fates are induced over proximal by inhibiting endogenous production of RA through the application of the biosynthesis inhibitor N,N-diethlyaminobenzaldehyde (DEAB) ([@bib63]; [@bib62]). Through expression profiling and subsequent functional studies, several transcription factors have been mapped as acting downstream of RA signaling to regulate pronephros segmentation and epithelial fate choice, including *hepatocyte nuclear factor-1 beta* (paralogues *hnf1ba* and *hnf1bb*), *iroquois homeobox 3b* (*irx3b*), *mds1/evi1 complex* (*mecom*), *single minded family bHLH transcription factor 1a* (*sim1a*), and *t-box 2* (paralogues *tbx2a* and *tbx2b*), among others ([@bib62]; [@bib46]; [@bib34]; [@bib30]; [@bib7]; [@bib38]; [@bib36]; [@bib12]). Despite these advances, the identity of the other essential signals that control renal progenitor fate decisions has remained elusive ([@bib6]).

Historically, prostaglandins have been defined as functionally diverse molecules that regulate an array of biological tasks, including inflammation and vasoregulation ([@bib16]; [@bib58]). With regard to the adult kidney, prostaglandins regulate many aspects of renal physiology, ranging from tubular transport processes to hemodynamics ([@bib45]). Prostaglandins are lipid mediators produced by the sequential actions of a series of enzymes, and exert their effects by paracrine or autocrine signaling through distinct G-protein coupled receptors ([@bib16]; [@bib58]). More specifically, there are five major prostaglandins produced from the precursor arachidonic acid (AA) by the enzymes Prostaglandin-endoperoxide synthase one or Prostaglandin-endoperoxide synthase 2a (Ptgs1 and Ptgs2a in zebrafish, also known as cyclooxygenases COX-1 and COX-2 in mammals) followed by subsequent processing by particular synthases ([@bib16]; [@bib58]). Each bioactive prostanoid interacts with one or more G-protein coupled membrane receptors ([@bib16]; [@bib58]). For example, COX activity on AA can generate the intermediate PGH~2~, from which the PGE~2~ bioactive can be produced by the prostaglandin E synthase (Ptges) ([Figure 1E](#fig1){ref-type="fig"}). PGE~2~ will signal by subsequent interactions with Ptger G-protein coupled receptors including EP1, EP2, EP3 and EP4 (known as Ptger1-4 in zebrafish) on receiving cells ([Figure 1E](#fig1){ref-type="fig"}) ([@bib16]; [@bib58]; [@bib64]).

While prostaglandin biosynthesis and signal transduction have been extensively studied in both healthy and diseased adult tissues ([@bib39]; [@bib56]), knowledge of their roles in development have been more challenging to ascertain for several reasons. Firstly, although it is thought that various factors that produce prostaglandins are broadly expressed during ontogeny, precise knowledge about the spatiotemporal progression of particular pathway components is incomplete. Secondly, there is a substantial void in our understanding due to the results of murine loss of function studies where genetic disruptions of components within the prostaglandin pathway was associated with observably normal development. This led to the hypothesis that maternal prostaglandin sources had rescued embryogenesis, thereby complicating the use of mammalian models to study prostaglandin requirements during ontogeny. The importance of reevaluating prostaglandin signaling in kidney formation has been emphasized by a recent report that COX-2 dosage is critical for murine metanephros development, though it is presently enigmatic whether there are requirement(s) for discrete stages of nephrogenesis ([@bib55]).

In lieu of the challenges of using mammalian systems to delineate the roles of prostaglandin signaling during development, considerable insights in vertebrates have nevertheless been achieved recently through research using the zebrafish model. Most notably, there have been transformative revelations regarding the conserved roles of prostaglandin signaling during definitive blood formation, where PGE~2~ was found to regulate hematopoietic stem cell (HSC) development and function ([@bib48]). A chemical genetic screen in zebrafish also identified the prostaglandin pathway as a modifier of endoderm organogenesis, where in subsequent work it was found that PGE~2~ activity controls opposing cell fate decisions in the developing pancreas and liver through the *ep4a* receptor (also known as *ptger4a*), which derive from a bipotential endoderm progenitor ([@bib17]; [@bib47]). Other than these studies, there is little known about how prostaglandin signaling may affect cell fate decisions during the emergence of other vertebrate tissues.

Here, we report the discovery that PGE~2~ signaling has potent effects in regulating proximal and distal segment formation during nephrogenesis in the developing zebrafish kidney. Using the zebrafish embryo for gain and loss of function studies, in addition to whole mount *in situ* hybridization (WISH) to profile gene expression, we uncovered that the Cox enzymes Ptgs1 and Ptgs2a, as well as the PGE~2~ receptors Ptger2a and Ptger4a, are necessary to properly establish distal nephron segment boundaries during pronephros genesis. Further, we found that addition of PGE~2~ was sufficient to rescue distal segmentation in Ptgs1 and Ptgs2a deficient zebrafish. Interestingly, treatment with exogenous PGE~2~ or PGB~2~ during nephrogenesis induced a striking expansion of a proximal tubule segment lineage in a dosage-dependent manner. Taken together, this work reveals for the first time that alterations in PGE~2~ signaling, and possibly other prostaglandins as well, has important consequences for the developing nephron.

Results {#s2}
=======

Chemical genetic screen reveals that prostaglandin levels affect nephron development {#s2-1}
------------------------------------------------------------------------------------

To date, much remains unknown concerning the factors that control nephron segment development and cell fate decisions. The zebrafish pronephros is an experimentally tractable system to interrogate the genetic factors that regulate nephrogenesis because of its simple, conserved tubule structure, with two proximal segments and two distal segments ([Figure 1A](#fig1){ref-type="fig"}) ([@bib14]; [@bib13]). The nephrons share a blood filter comprised of podocyte cells (P), followed by a neck (N) segment that transports fluid into the tubule, and finally a pronephric duct (PD) that drains caudally at the cloaca (C), a common exit for the kidney and gut in the embryo ([Figure 1A](#fig1){ref-type="fig"}, middle panel). Nephron segment fates are established by the 24 hpf stage, based on the expression of unique solute transporters, and each segment has been mapped to a precise axial location relative to the somites that comprise the embryonic trunk ([Figure 1A](#fig1){ref-type="fig"}, bottom panel), which facilitates the analysis of pattern formation within the renal progenitor field ([@bib63]).

Chemical genetics is a powerful approach to study developmental events in the context of the whole organism, and the application of chemical genetics in the zebrafish has led to a number of valuable discoveries about the mechanisms of organogenesis in diverse tissues, including derivatives of the mesoderm ([@bib33]; [@bib52]). Therefore, we hypothesized that a chemical genetic screen could provide new insights about the identity of nephrogenesis regulators. To this end, we performed a chemical genetic screen using the Screen-Well ICCB Known Bioactives Library (Enzo Life Sciences), a collection that includes 480 compounds with known biological activities. Zebrafish embryos were collected from timed matings of wild-type (WT) adults, and then arrayed in 96-well plates for control (dimethyl sulfoxide, DMSO) or experimental treatment between 4 and 24 hpf ([Figure 1B](#fig1){ref-type="fig"}). At the 24 hpf stage, embryos were fixed for multiplex WISH analysis, during which they were assessed for expression of a set of genetic markers that distinguished alternating nephron segments within the pronephros, namely *wt1b* to directly label the P, *slc20a1a* to label the PCT, and *slc12a1* to label the DE ([Figure 1B](#fig1){ref-type="fig"}). Because these riboprobes stain alternating nephron segments, they enabled precise scoring as to whether exposure to each chemical led to an expansion or restriction of these distinct cell types ([Figure 1C](#fig1){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}).

In total, 16.25% (78/480) of ICCB bioactives were associated with nephron phenotypes ([Figure 1C](#fig1){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). The effect of each compound was annotated as to whether the experimental dosage was associated with WT development, an expansion in segment(s) (P+, PCT+, DE+) or a restriction in segment(s) (P-, PCT-, DE-) ([Figure 1C](#fig1){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). The compounds that led to alterations in nephrogenesis included numerous RA pathway agonists and antagonists, such as 4-hydroxyphenylretinamide (4-HPR), a synthetic analog of all-trans RA ([Figure 1D](#fig1){ref-type="fig"}) ([@bib50]). Compared to WTs, exposure to 1 mM 4-HPR led to an expansion of the PCT, caudal shift of the DE, and a dramatic expansion of the interval between these segments where the PST normally emerges, suggestive of an expanded PST segment ([Figure 1D](#fig1){ref-type="fig"}) ([@bib50]). The observation that molecules which impact the RA pathway were flagged as hits in the screen provided an important positive control for our experimental system, given the well-established effects of RA levels on renal progenitors ([@bib63]; [@bib62]; [@bib34]; [@bib7]; [@bib38]; [@bib12]).

In further surveying the identities and respective classifications of the small molecules that impacted nephrogenesis, we noted a striking trend with regard to prostaglandin pathway agonists and tubule segmentation. Among the screen hits, a series of prostaglandin cytokine moieties were independently flagged as modifiers of tubule segment formation, including PGD~2~, PGA~1~, PGJ~2~, and PGB~2~ ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). Exposure to these bioactive prostaglandins was associated with changes in the pronephros whereby there was a reduced PCT segment length and a posterior shift in the position of the DE, such that there was a noticeably longer domain between these segment regions compared to WT control embryos ([Figure 1D](#fig1){ref-type="fig"}). The discovery that exposure to exogenous prostaglandins was linked with several segmentation changes was particularly fascinating to us because PGE~2~ signaling has been associated recently with the development of several tissues, including HSCs and fate choice in endoderm derivatives between the liver and pancreas ([@bib48]; [@bib47]). Therefore, we next sought to further explore how elevated prostaglandin levels, including PGE~2~, affected nephron segment development.

Elevated PGE~2~ or PGB~2~ levels induce an expansion of the PST segment and DL reduction {#s2-2}
----------------------------------------------------------------------------------------

Prostaglandins typically have a short half-life, and have been characterized as secreted molecules that activate receptors close to their site of production, thus inducing local effects in a paracrine or autocrine fashion ([@bib56]). Prostaglandins have also been shown to elicit dosage-specific effects, leading to their description as morphogens ([@bib47]). Therefore, to validate and further explore the screening results, we selected two prostanoids: one was a hit from our screen, PGB~2~, and the other was 16,16-dimethyl-PGE~2~ (dmPGE~2~), a long-acting derivative of PGE~2~ which has been extensively used to study the effects of PGE~2~ in zebrafish ([@bib48]; [@bib21]; [@bib47]). WT embryos were collected and incubated in varying concentrations of drug (30 μM, 50 μM, 80 μM or 100 μM) from the 4 hpf stage to the 24 hpf stage. Double WISH was then performed to determine the resultant nephron segments alongside the trunk somites, and the absolute lengths of nephron segment domains were also measured ([Figure 2](#fig2){ref-type="fig"}, [Figure 2---figure supplements 1](#fig2s1){ref-type="fig"} and [2](#fig2s2){ref-type="fig"}).10.7554/eLife.17551.004Figure 2.Exogenous prostaglandin activity promotes proximal straight tubule identity.(**A**) Embryos were exposed to 100 µM dmPGE~2~ between 4 hpf and 24 hpf. WISH was used to stain for the PCT (*slc20a1a*), PST (*trpm7*), DE (*slc12a1*), and DL (*slc12a3*) (purple) and the somites (*smyhc1*) (red) at the 24 hpf stage. Black bars indicate segment gene expression domain. Red scale bar, 70 µm. (**B**,**C**) The PST and DL segments were measured in microns after incubation in 100 μM of dmPGE~2~ (n = 5 for each control and experimental group). (**D**) Summary depicting the nephron segments after exogenous dmPGE~2~ treatment. Data are represented as ± SD, significant by t test comparing each drug treatment to the DMSO control, \*p\<0.05, \*\*\*p\<0.0005.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.004](10.7554/eLife.17551.004)10.7554/eLife.17551.005Figure 2---figure supplement 1.Exogenous PGB~2~ treatment is sufficient to expand the proximal straight tubule.(**A**) Embryos were treated with PGB~2~ at 100 μM from 4 hpf to 24 hpf. Using WISH, embryos were stained for the PCT (*slc20a1a*), PST (*trpm7*), DE (*slc12a1*), and DL (*slc12a3*) (purple) and the somites (*smyhc1*) (red) at the 24 hpf stage. Black bars indicate segment gene expression domain. Red scale bar, 70 µm. (**B**) Summary depicting the nephron segments after PGB~2~ treatment at 100 μM.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.005](10.7554/eLife.17551.005)10.7554/eLife.17551.006Figure 2---figure supplement 2.dmPGE~2~ and PGB~2~ treatment have dosage-dependent effects on pronephros segmentation.(**A**--**D**) Embryos were incubated from 4 hpf to 24 hpf in 30 μM, 50 μM, 80 μM, and 100 μM solutions of dmPGE~2~ or PGB~2~. The PCT (*slc20a1a*), PST (*trpm7*), DE (*slc12a1*), and DL (*slc12a3*) (purple) and the somites (*smyhc1*) (red) were then stained at the 24 hpf stage for using WISH and quantified in triplicate per phenotype. Increments of greater than (\>) or less than (\<) were used to categorize segment changes, where each (\>) or (\<) represents a difference in segment area of one somite. At least 15 embryos were used per each control and experimental group. (**E**, **F**) The PCT and DE segments were measured in microns after incubation in 100 μM of dmPGE~2~ (n = 5 for each control and experimental group). Data are represented as ± SD, significant by t test comparing each drug treatment to the DMSO control, \*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.0005, \*\*\*\*p\<0.00005, \*\*\*\*\*p\<0.000005, where n.s. indicates not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.006](10.7554/eLife.17551.006)10.7554/eLife.17551.007Figure 2---figure supplement 3.Embryos dimensions remain largely unchanged by dmPGE~2~ or indomethacin treatment.(**A**) The pronephric domain (starting at the beginning somite five to the end of somite 18) was measured in microns for embryos treated with 1% DMSO, 100 μM dmPGE~2~, or 30 μM indomethacin from 4 hpf to 24 hpf (n = 5). (**B**) The body axis domain at the 24 hpf stage was measured for embryos exposed to 1% DMSO, 100 μM dmPGE~2~, and 30 μM indomethacin. (**C**) An image of a 24 hpf embryo stained for *slc12a1* and *smyhc1*, where black bars label the pronephric domain and the body axis domain. Red scale bar, 70 µm. Data are represented as ± SD, ANOVA used to compare samples, where n.s. indicates not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.007](10.7554/eLife.17551.007)10.7554/eLife.17551.008Figure 2---figure supplement 4.Perturbation of the prostaglandin pathway fails to elicit gross blood or blood vessel abnormalities during development.Embryos were treated with 1% DMSO, 30 μM indomethacin, or 100 μM dmPGE~2~ from 4 hpf to 24 hpf and WISH was performed to detect (**A**) vasculature (*flk1*) and (**B**) blood precursors (*gata1*) at the 24 hpf stage. (**C**) o-dianisidine staining was performed at the 55 hpf stage on embryos treated with 1% DMSO, 30 μM indomethacin, and 100 μM dmPGE~2~ from 4 hpf to 24 hpf in triplicate with at least 30 embryos. Red scale bar, 70 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.008](10.7554/eLife.17551.008)

Exposure to dmPGE~2~ or PGB~2~ resulted in a dose-dependent increase in the domain length of the PST segment compared to WT embryos, visualized by WISH with the marker *trpm7* ([Figure 2A,B](#fig2){ref-type="fig"}, [Figure 2---figure supplements 1](#fig2s1){ref-type="fig"},[2](#fig2s2){ref-type="fig"}). In conjunction with this change, the DL segment was significantly reduced in length, as visualized by WISH with the marker *slc12a3* ([Figure 2A,C](#fig2){ref-type="fig"}, [Figure 2---figure supplements 1](#fig2s1){ref-type="fig"},[2](#fig2s2){ref-type="fig"}). Additionally, the rostral domain of the PCT was reduced in a dosage-dependent fashion, based on expression of *slc20a1a* ([Figure 2A,D](#fig2){ref-type="fig"}, [Figure 2---figure supplements 1](#fig2s1){ref-type="fig"},[2](#fig2s2){ref-type="fig"}). Further, there was a caudal shift in the position of the DE segment though its absolute length was unchanged, based on expression of the DE-specific marker *slc12a1*, which resides between the domains of the PST and DL segments ([Figure 2A,D](#fig2){ref-type="fig"}, [Figure 2---figure supplements 1](#fig2s1){ref-type="fig"},[2](#fig2s2){ref-type="fig"}). Overall, these results recapitulated the phenotypes observed following treatment with various bioactive prostaglandins during the chemical screen ([Figure 1D](#fig1){ref-type="fig"}). To determine if embryo dimensions were a factor in pronephros segment domain changes, we measured control and treated embryos from tip to tail as well as their pronephric domain (somite 3 to somite 18). We found no statistical differences in the body axis length or pronephric domain between WT controls and dmPGE~2~ treated embryos ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). To further gauge the possible side effects of dmPGE~2~ treatment on surrounding tissues, we assessed development of specific tissues using WISH. We noted no significant changes in the vascular marker *flk1* or primitive blood precursors using the marker *gata1* between WT controls and 100 μM dmPGE~2~ treated embryos ([Figure 2---figure supplement 4A,B](#fig2s4){ref-type="fig"}). Furthermore, we performed o-dianisidine staining, which labels hemoglobinized erythrocytes and thereby provides a sensitive assessment of defects in circulation or vascular integrity that can be undetected by live imaging with stereomicroscopy. o-dianisidine staining showed that blood flow in WTs and 100 μM dmPGE~2~ treated embryos was equivalent through the 48--55 hpf stage, as we did not observe compromised vessel integrity or hematomas (e.g. bleeding, blood pooling) ([Figure 2---figure supplement 4C](#fig2s4){ref-type="fig"}). This suggests that PGE~2~ exposure did not cause major aberrations in tissues surrounding the pronephros. In sum, these observations confirmed the finding from the chemical screen that exogenous PGB~2~ had profound effects on nephron segment formation, and revealed that alterations in PGE~2~ had similar consequences.

Expression of Ptges enzymes is required for normal distal pronephros segment development {#s2-3}
----------------------------------------------------------------------------------------

Next, we determined whether endogenous prostaglandin biosynthesis mediated by the Ptges (e.g. Cox1, Cox2) enzymes was necessary for normal nephron segmentation. To test this, we incubated WT embryos with the compound indomethacin, a nonselective Cox1 and Cox2 enzyme inhibitor, which inhibits the first stage of prostanoid biosynthesis, and has been shown to suppress PGE~2~ production in zebrafish by mass spectrometry ([Figure 1E](#fig1){ref-type="fig"}, [Figure 3](#fig3){ref-type="fig"}) ([@bib22]; [@bib2]; [@bib48]). Exposure of WT embryos to 30 μM indomethacin was associated with normal proximal segment locations along the embryonic trunk ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). However, the balance of distal segments was disrupted after indomethacin treatment, such that the majority of embryos developed an *slc12a1*-expressing DE segment that was significantly expanded in length and an *slc12a3*-expressing DL segment that was significantly reduced in length compared to wild-type controls ([Figure 3A,B and C](#fig3){ref-type="fig"}). Absolute segment length measurements of the proximal domains in indomethacin treated embryos compared to wild-types confirmed there was no significant change in the lengths of these segments ([Figure 3D](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). As with dmPGE2 treated embryos, we assessed the effect of indomethacin exposure at this dosage with various morphological dimensions and the formation of surrounding tissues such as the vasculature, and observed no differences compared to WT controls ([Figure 2---figure supplements 3](#fig2s3){ref-type="fig"},[4](#fig2s4){ref-type="fig"}).10.7554/eLife.17551.009Figure 3.Prostaglandin production is required for normal distal cell fate specification.(**A**) Embryos were treated with 0.3% DMSO or the nonselective Cox inhibitor indomethacin at 30 μM from 4 hpf to 24 hpf. WISH was used to stain for the PCT (*slc20a1a*), PST (*trpm7*), DE (*slc12a1*), and DL (*slc12a3*) (purple) and the somites (*smyhc1*) (red) at the 24 hpf stage. Black bars indicate segment gene expression domain. Red scale bar, 70 µm. (**B,C**) The DE and DL segments were measured in microns (n = 5 for each control and experimental group). (**D**) A summary depicting the nephron segments after indomethacin treatment. Data are represented as ± SD, significant by t test comparing each drug treatment to the DMSO control group, \*\*p\<0.005.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.009](10.7554/eLife.17551.009)10.7554/eLife.17551.010Figure 3---figure supplement 1.Indomethacin treatment has no effect on proximal cell-fate choice, yet shifts the balance between distal identities.(**A**) The PCT (*slc20a1a*), PST (*trpm7*), DE (*slc12a1*), and DL (*slc12a3*) (purple) and the somites (*smyhc1*) (red) were quantified at the 24 hpf stage in triplicate according to changes in domain size after 30 μM indomethacin incubation from 4 hpf to 24 hpf. Greater than (\>) and less than (\<) were used to categorize embryos, where each (\>) or (\<) represents the difference of a somite change in segmentation. At least 20 embryos were used per control and experimental group. Data are represented as ± SD significant by t test comparing each drug treatment to corresponding DMSO control group, \*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.0005, where n.s. indicates not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.010](10.7554/eLife.17551.010)

To further explore these results, we examined the effect of other small molecules that have been validated to interfere with Cox enzyme activity. Treatment with the Ptgs1 (Cox1) selective inhibitor SC-560 or the Ptgs2a (Cox2) selective inhibitor NS-398 ([@bib22]; [@bib2]; [@bib48]) induced an expansion of the DE segment and a restriction of the DL compared to wild-type embryos, while having no discernible effect on proximal segment development ([Figure 4](#fig4){ref-type="fig"}, [Figure 4---figure supplements 1](#fig4s1){ref-type="fig"} and [2](#fig4s2){ref-type="fig"}). The DE and DL segment domain phenotypes following SC-560 or NS-398 treatment were statistically significant based on absolute length analysis compared to wild-type controls ([Figure 4---figure supplement 9](#fig4s9){ref-type="fig"}).10.7554/eLife.17551.011Figure 4.Prostaglandin signal inhibition results in an expansion of the distal early domain, which is rescued by the addition of exogenous dmPGE~2~.Embryos were treated with a (**A**) 1% DMSO control, the (**B**) Ptgs1 selective inhibitor SC-560 at 50 μM from 4 hpf to 24 hpf, microinjected with the *ptgs1* MO alone, or microinjected with the *ptgs1* MO and treated with dmPGE~2~ from 4 hpf to 24 hpf. Embryos were treated with the (**C**) Ptgs2a selective inhibitor NS-398 at 50 μM from 4 hpf to 24 hpf, microinjected with the *ptgs2a* MO or microinjected with the *ptgs2a* MO and then treated with dmPGE~2~ at 50 μM from 4 hpf to 24 hpf. (**D**) Embryos were microinjected with a combination of the *ptgs1* MO and *ptgs2a* MO. Embryos were microinjected with (**E**) *ptger2a* MO1, *ptger2a MO2*, (**F**) *ptger4a MO1* and *ptger4a MO2*. (**A**--**E**) WISH was used to stain for the DE (*slc12a1*), DL (*slc12a3*) (purple), and the somites (*smyhc1*) (red) at the 24 hpf stage. Black bars indicate segment gene expression domain. Red scale bar, 70 µm. (**G**) Summary depicting the nephron segments after inducing deficiency of prostaglandin synthesis or receptor activity.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.011](10.7554/eLife.17551.011)10.7554/eLife.17551.012Figure 4---figure supplement 1.Inhibition of Ptgs1 or Ptgs2a did not alter proximal segment identity.Embryos were treated with (**A**). 5% DMSO, (**B**) the selective Ptgs1 inhibitor SC-560 at 50 μM, and (**E**) the selective Ptgs2a inhibitor NS-398 at 50 μM from 4 hpf to 24 hpf. Embryos were microinjected with (**C**) *ptgs1 MO*, (**F**) *ptgs2a MO* or (**H**) both *ptgs1 MO* and *ptgs2a MO* together and grown until 24 hpf. Embryos were microinjected with (**D**) *ptgs1* MO or (**G**) *ptgs2a* MO then exposed to 100 μM dmPGE~2~ from 4 hpf to 24 hpf. WISH was used to label the PCT (*slc20a1a*) and PST (*trpm7*) (purple) as well as the somites (*smyhc1*) (red) at the 24 hpf stage. Black bars indicate segment gene expression domain. Red scale bar, 70 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.012](10.7554/eLife.17551.012)10.7554/eLife.17551.013Figure 4---figure supplement 2.Diminishing Ptgs1 or Ptgs2a function causes distal early cell-fate identity to be favored at the expense of the distal late domain.(**A**) The PCT, (**B**) PST, (**C**) DE, and (**D**) DL segment phenotypes were quantified in triplicate at the 24 hpf stage according to comparisons to the somites for *ptgs1/2a* double *MO*, *ptgs1 MO*, *ptgs2a MO*, *ptgs1* splice *MO*, and *ptgs2a* splice *MO* microinjections, SC-560 and NS-398 at 50 μM from 4 hpf to 24 hpf, and for embryos microinjected with either *ptgs1 MO* or *ptgs2a MO* and treated with dmPGE~2~ at 50 μM from 4 hpf to 24 hpf. Greater than (\>) and less than (\<) were used to categorize embryos, where each (\>) or (\<) represents the difference of a somite change in segmentation. At least 15 embryos were used per control and experimental group. Data are represented as ± SD significant by t test comparing each drug treatment to the corresponding DMSO control group, \*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.0005, \*\*\*\*p\<0.00005, where n.s. indicates not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.013](10.7554/eLife.17551.013)10.7554/eLife.17551.014Figure 4---figure supplement 3.Inhibiting prostaglandin synthesis with splice morpholinos promotes distal early identity.(**A**) WT embryos were microinjected with either *ptgs1 MO* splice or *ptgs2a MO* splice and grown until 24 hpf. WISH was used to assay for the PCT (*slc20a1a*), PST (*trpm7*), DE (*slc12a1*), and DL (*slc12a3*) (purple) and the somites (*smyhc1*) (red) at the 24 hpf stage. Black bars indicate segment gene expression domain. Red scale bar, 70 µm. (**B**) A somite summary map depicting the changes induced by *ptgs1 MO* splice and *ptgs2a MO* splice microinjection.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.014](10.7554/eLife.17551.014)10.7554/eLife.17551.015Figure 4---figure supplement 4.The prostaglandin receptor transcripts *ptger2a* and *ptger4a* are expressed in the pronephros during development and co-localize with the nephron.WT embryos from the 12 ss through 26 ss were stained for (**A**) *ptger2a* or (**B**) *ptger4a* transcript expression (purple) and the somites (red) using WISH. The *ptger2a* and *ptger4a* expression domains are framed in black boxes. WT embryos at the 14 ss and 18 ss were co-stained for (**C**) *ptger2a* and *cdh17* (**D**) and *ptger4a* and *cdh17*, where transcripts encoding the latter mark the entire nephron. Asterisks demarcate co-localization between markers. Black bars indicate receptor gene expression domain. Red scale bar, 70 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.015](10.7554/eLife.17551.015)10.7554/eLife.17551.016Figure 4---figure supplement 5.Morpholino inhibition of *ptger2a* fails to affect proximal segment identity.(**A**) Embryos were microinjected with *ptger2a MO1* or *MO2* and grown until 24 hpf. WISH was used to visualize the PCT (*slc20a1a*) and PST (*trpm7*) (purple) and the somites (red) at the 24 hpf stage. Black bars indicate segment gene expression domain. Red scale bar, 70 µm. (**B**) Segment areas for the PCT, PST, DE, and DL were quantified in triplicate using parallel somites. Greater than (\>) and less than (\<) were used to categorize embryos, where each (\>) or (\<) represents the difference of a somite in segment area. At least 20 embryos were used per control and experimental group. Data are represented as ± SD significant by t test comparing each drug treatment to the corresponding DMSO control group, \*p\<0.05, \*\*p\<0.005, where n.s. indicates not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.016](10.7554/eLife.17551.016)10.7554/eLife.17551.017Figure 4---figure supplement 6.Inhibition of *ptger2a* using small molecule antagonists promotes distal early fate-choice.(**A**) Embryos were exposed to 0.1% DMSO, 3 μM AH6809, or 3 μM PF04418948 from 4 hpf to 24 hpf. WISH was used to stain for the PCT (*slc20a1a*), PST (*trpm7*), DE (*slc12a1*), and DL (*slc12a3*) (purple) and the somites (*smyhc1*) (red) at the 24 hpf stage. Black bars indicate segment gene expression domain. Red scale bar, 70 µm. (**B**) A somite summary schematic describing the changes in patterning caused by *ptger2a* antagonist treatment. (**C**) The PCT, PST, DE, and DL segments were quantified per phenotype in triplicate using juxtaposed somites. Greater than (\>) and less than (\<) were used to categorize embryos, where each (\>) or (\<) represents the difference of a somite in the pertinent segment area. At least 20 embryos were used for each control and experimental group. Data are represented as ± SD significant by t test comparing each drug treatment to the corresponding DMSO control group, \*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.0005, where n.s. indicates not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.017](10.7554/eLife.17551.017)10.7554/eLife.17551.018Figure 4---figure supplement 7.*ptger4a* MO knockdown results in an expansion of the distal early segment.(**A**) Embryos were microinjected with *ptger4a MO1* or *ptger4a* MO2 and grown until 24 hpf. Embryos were stained for the PCT (*slc20a1a*), PST (*trpm7*), (purple) and the somites (*smyhc1*) (red) using WISH at the 24 hpf stage. Black bars indicate segment gene expression domain. Red scale bar, 70 µm. (**B**) The PCT, PST, DE, and DL were quantified in triplicate using parallel somites to categorize phenotypes. Greater than (\>) and less than (\<) were used to categorize embryos, where each (\>) or (\<) represents the difference of a somite in the pertinent segment area. At least 20 embryos were used for each control and experimental group. Data are represented as ± SD significant by t test comparing each drug treatment to the corresponding DMSO control group, \*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.0005, \*\*\*\*p\<0.00005, where n.s. indicates not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.018](10.7554/eLife.17551.018)10.7554/eLife.17551.019Figure 4---figure supplement 8.Exogenous dmPGE~2~ is incapable of rescuing distal cell fates in Ptger2a or Ptger4a deficient morphant embryos.Embryos were microinjected with either (**A**) *ptger2a MO1* or (**B**) *ptger4a MO1* and treated with. 5% DMSO or 50 μM dmPGE~2~ from 4 hpf to 24 hpf. WISH was used to label the DE (*slc12a1*), and DL (*slc12a3*) (purple) and the somites (*smyhc1*) (red) at the 24 hpf stage. Black bars indicate segment gene expression domain. Red scale bar, 70 µm. (**C**) The DE and DL were measured in microns for each control and experimental group (n = 5 for each). Data are represented as ± SD, ANOVA used to compare samples, \*p\<0.01, where n.s. indicates not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.019](10.7554/eLife.17551.019)10.7554/eLife.17551.020Figure 4---figure supplement 9.Inhibiting PGE~2~ production results in an expanded distal early domain at the expense of the distal late segment, which can be rescued by exogenous dmPGE~2~.Embryos were microinjected with *ptsgs1/2a MO*, *ptgs1 MO*, *ptgs2a MO*, *ptger2a MO1*, *ptger2a MO2*, *ptger4a MO1*, and *ptger4a MO2* and were allowed to develop until 24 hpf. Embryos were also microinjected with *ptgs1 MO* and *ptgs2a MO* and treated with 50 μM dmPGE~2~ from 4 hpf to 24 hpf. Embryos were also subjected to 50 μM SC-560, 50 μM NS-398, 3 μM AH6809, and 3 μM PF04418948 from 4 hpf to 24 hpf. The (**A**) DE (*slc12a1*) and (**B**) DL (*slc12a3*) domains were measured in microns following WISH (n = 5 for each control an dexperimental group) at the 24 hpf stage. Data are represented as ± SD significant by t test comparing each drug treatment to the corresponding DMSO control group, \*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.0005, \*\*\*\*p\<0.00005, where n.s. indicates not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.020](10.7554/eLife.17551.020)10.7554/eLife.17551.021Figure 4---figure supplement 10.Validation of transcriptional changes using splice morpholinos to target *ptgs1, ptgs2a*, *ptger2a*, and *ptger4a*.Embryos were microinjected with morpholino and allowed develop until 24 hpf, where their RNA was then harvested for RT-PCR. Schematics illustrate each genetic locus, with the location targeted by the MO(s) and primers used for transcriptional analysis on 2% agarose gels. (**A**) *ptgs1* knockdown targeted the exon one splice donor site, and caused inclusion of the 91 bp intron 1--2 that encodes a premature stop codon in *ptgs1* transcripts in morpholino-injected zebrafish. (**B**) *ptgs2a* knockdown targeted the exon three splice donor site, and caused inclusion of the 111 bp intron 3--4 that encodes a premature stop codon in *ptgs2a* transcripts in morpholino-injected zebrafish. (**C**) *ptger2a* knockdown as well as (**D**) *ptger4a* knockdown targeted the exon one splice donor and exon two splice acceptor site in *ptger2a* and *ptger4a*, respectively. Green asterisks in these gel images indicate the complete absence of the WT PCR product in the morphant samples. We were unable to PCR across the entire intron of either gene due to their sizes. However, in contrast to WT samples, we detected *ptger2a* and *ptger4a* transcripts that included intronic sequence in the respective morphant samples. In each case, inclusion of the intron is predicted to encode a truncated peptide. (**E**) Embryos were microinjected at the 1-cell stage with either *ptger2a MO* splice (MO3/MO4 combination) or the *ptger4a MO* splice (MO3/MO4 combination) and allowed to developed until 24 hpf, where WISH was used to stain for the DL (*slc12a3*) segment. Black bars indicate segment gene expression domain. Red scale bar, 70 µm. (**F**) The DL domain was measured in WT controls, *ptger2a MO* splice (MO3/MO4 combination) or the *ptger4a MO* splice (MO3/MO4 combination) in microns (n = 5 for each control and experimental group). Data are represented as ± SD, ANOVA used to compare samples, \*p\<0.01, where n.s. indicates not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.021](10.7554/eLife.17551.021)

To corroborate the effects we observed on zebrafish distal nephron segment development from Cox1/2 enzyme inhibition, we generated *ptgs* knockdowns through microinjection of previously described translation blocking morpholinos to target *ptgs1*, *ptgs2a,* or both *ptgs1/2a* into 1-cell stage WT embryos ([@bib22]; [@bib48]). Nephron segmentation was analyzed at the 24 hpf stage by WISH with the panel of specific markers to delineate the domains of the PCT, PST, DE and DL (*slc20a1a, trpm7, slc12a1* and *slc12a3*, respectively) as well as the somites (*smyhc1*). Single and double *ptgs1/2a* morphants developed a larger DE domain that was increased in length compared to WT control embryos ([Figure 4B--4D](#fig4){ref-type="fig"}, [Figure 4---figure supplements 1](#fig4s1){ref-type="fig"}, [2](#fig4s2){ref-type="fig"} and [9](#fig4s9){ref-type="fig"}). In addition, single and double *ptgs1/2a* morphants had a shortened DL segment compared to the DL in WT control embryos ([Figure 4B--4D](#fig4){ref-type="fig"}, [Figure 4---figure supplements 1](#fig4s1){ref-type="fig"}, [2](#fig4s2){ref-type="fig"} and [9](#fig4s9){ref-type="fig"}). These DE and DL segment domain phenotypes were all statistically significant based on absolute length analysis compared to WT controls ([Figure 4---figure supplement 9](#fig4s9){ref-type="fig"}). In contrast, PCT and PST segment development was normal in *ptgs1*, *ptgs2a,* or *ptgs1/2a* deficient embryos at the 24 hpf stage ([Figure 4---figure supplements 1](#fig4s1){ref-type="fig"} and [2](#fig4s2){ref-type="fig"}).

To further validate these findings, we conducted independent analysis of *ptgs1* or *ptgs2a* morpholinos that were confirmed to interfere with mRNA splicing, by which inclusion of an intron was found to generate transcripts encoding prematurely truncated proteins ([Figure 4---figure supplement 10](#fig4s10){ref-type="fig"}). Compared to wild-type controls, both of these *ptgs1* and *ptgs2a* splice morpholinos similarly affected pronephros development by causing a DE expansion and a DL reduction, with no perceivable consequence to the proximal segments ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). Again, the segment domain findings were statistically significant based on absolute segment length analysis with WT controls ([Figure 4---figure supplement 9](#fig4s9){ref-type="fig"}). Taken together, these data provide independent validation that expression of both *ptgs1* and *ptgs2a* are critical for normal formation of the DE and DL segments in the zebrafish pronephros.

PGE~2~ rescues nephron development in Ptgs-deficient zebrafish embryos {#s2-4}
----------------------------------------------------------------------

Next, we tested whether distal nephron segmentation in *ptgs1* and *ptgs2a* deficient embryos could be rescued by provision of a bioactive prostanoid. For these experiments, we selected dmPGE~2~ treatment, in part to test the hypothesis that PGE~2~ signaling is required for pronephros development. WT embryos were injected with *ptgs1* and *ptgs2a* morpholinos and then subsequently treated with 50 μM dmPGE~2~ between the 4 hpf stage and the 24 hpf stage. Nephron segments were then assessed by WISH using our panel of segment-specific riboprobes. We observed that the alterations in DE and DL segments in *ptgs1* and *ptgs2a* deficient embryos were indeed rescued by exposure to dmPGE~2~, a treatment combination that was again not associated with altered proximal segment domains ([Figure 4B,C](#fig4){ref-type="fig"}, [Figure 4---figure supplements 1](#fig4s1){ref-type="fig"}, [2](#fig4s2){ref-type="fig"} and [9](#fig4s9){ref-type="fig"}). Notably, the *ptgs1* and *ptgs2a* morphants treated with dmPGE~2~ exhibited statistically similar DE and DL segment lengths compared to WT controls, in contrast to the longer DE and shortened DL in *ptgs1* and *ptgs2a* morphants treated with DMSO vehicle ([Figure 4---figure supplement 9](#fig4s9){ref-type="fig"}). These data indicate that the expansion of the DE segment and the restriction of the DL in *ptgs1* and *ptgs2a* deficient embryos were caused specifically by diminished prostaglandin activity, and implicate PGE~2~ as the essential bioactive prostanoid because dmPGE~2~ was sufficient to rescue pronephros segmentation in the context of either Cox1 or Cox2 knockdown.

PGE~2~ regulates nephron segmentation via the *ptger2a* and *ptger4a* receptors {#s2-5}
-------------------------------------------------------------------------------

PGE~2~ is known to signal to its target cells by binding with the G-protein coupled receptor Prostaglandin E receptor 2a or the Prostaglandin E receptor 4a (Ptger2a, Ptger4a; also known as EP2 and EP4, respectively) ([@bib3]). PGE~2~ signaling in zebrafish acts through both Ptger2a and Ptger4a to modulate HSC formation ([@bib48]), and during endoderm specification, wherein the differential expression of these receptors mediates tissue development at discrete stages ([@bib47]). There has been some spatiotemporal expression analysis of these genes during zebrafish embryogenesis as well, which revealed that *ptger2a* transcripts were expressed at the six somite stage (ss) within bipotential endoderm progenitors and that *ptger4a* transcripts were expressed at 72 hpf within liver precursors ([@bib47]). However, further characterization of these genes' expression in relation to other organs, such as the kidney, has not been addressed.

Based on this, we examined if Ptger2a and/or Ptger4a expression was associated with any stages of pronephros development. We utilized WISH to determine the spatiotemporal expression of *ptger2a* and *ptger4a* transcripts between the tailbud stage and 24 hpf to determine if they localized to the areas occupied by the nephron progenitors ([Figure 4---figure supplement 4](#fig4s4){ref-type="fig"}). Interestingly, we found that *ptger2a* transcripts were expressed in a continuous stretch of IM renal progenitors between the 12 ss and 24 ss based on their location in bilateral stripes of cells situated adjacent to the paraxial mesoderm ([Figure 4---figure supplement 4A](#fig4s4){ref-type="fig"}). *ptger4a* transcripts were similarly expressed in the IM renal fields between the 12 ss and 15 ss, where cells expressed varying levels of signal, suggesting patches of somewhat variable expression ([Figure 4---figure supplement 4B](#fig4s4){ref-type="fig"}). *ptger4a* transcripts showed low levels of ubiquitous mesoderm expression at the 20 ss, and then were localized to the cloaca region at the 24 ss ([Figure 4---figure supplement 4B](#fig4s4){ref-type="fig"}). We next performed double WISH in WT embryos at the 14 ss and 18 ss to label *cadherin17* (*cdh17*) expressing renal progenitors along with either *ptger2a* or *ptger4a* ([Figure 4---figure supplement 4C](#fig4s4){ref-type="fig"}). As expected, *ptger2a* expressing cells in the IM fully occupied the bilateral stripes of *cdh17* expressing cells, as did *ptger4a*, though again we noted the slight variability of *ptger4a* transcript staining in cells residing within the *cdh17* pronephros fields ([Figure 4---figure supplement 4C](#fig4s4){ref-type="fig"}). These data were consistent with the notion that Ptger2a and/or Ptger4a may operate in renal progenitors to modulate their development.

To test the hypothesis that Ptger2a and/or Ptger4a function was necessary for pronephros segmentation, we next utilized previously published 5'UTR or start site targeting morpholinos to abrogate expression of either *ptger2a* or *ptger4a* transcripts during embryogenesis ([@bib3]; [@bib48]), as well as independent pharmacological treatments with two different Ptger2a receptor antagonists to block its activity ([Figure 4E,F](#fig4){ref-type="fig"}, [Figure 4---figure supplements 2](#fig4s2){ref-type="fig"} and [5](#fig4s5){ref-type="fig"}--[9](#fig4s9){ref-type="fig"}). Deficiency of *ptger2a* or *ptger4a* resulted in a statistically significant expansion of the DE segment and a reduction of the DL ([Figure 4E,F](#fig4){ref-type="fig"}, [Figure 4---figure supplements 2](#fig4s2){ref-type="fig"} and [5](#fig4s5){ref-type="fig"}--[9](#fig4s9){ref-type="fig"}). These data recapitulate the phenotypic effects that resulted from treatment with the Ptgs1/2a small molecule inhibitors, as well as deficiency of Ptgs1, Ptgs2a, and the combination of Ptgs1/2a ([Figure 4E](#fig4){ref-type="fig"}). We also specifically evaluated whether *ptger2a* or *ptger4a* knockdown could be rescued by dmPGE~2~, and found that dmPGE~2~ was not sufficient to rescue either the DE segment expansion or DL reduction ([Figure 4---figure supplement 8](#fig4s8){ref-type="fig"}). These findings are consistent with the notion that PGE~2~ acts specifically via Ptger2a and Ptger4a to mitigate DE-DL formation during pronephros ontogeny ([Figure 4---figure supplement 8](#fig4s8){ref-type="fig"}).

To further validate these observations and conclusions, we next examined pronephros segment development following morpholino-mediated knockdowns that were confirmed to alter the normal splicing of either *ptger2a* or *ptger4a* transcripts, and were consequently predicted to disrupt normal protein expression ([Figure 4---figure supplement 10](#fig4s10){ref-type="fig"}). We observed a statistically significant decrease in the length of the DL using these morpholinos, consistent with our previous observations with other knockdown reagents and pharmacological inhibitions, and thus lending further credence to the conclusion that DE and DL segmentation is reliant on Ptger2a or Ptger4a expression ([Figure 4---figure supplement 10](#fig4s10){ref-type="fig"}). Taken together, these data suggest that Ptger2a and Ptger4a have developmental roles in renal progenitors where they interact with PGE~2~ to regulate distal nephron segment formation.

Alterations in Ptgs activity or PGE~2~ levels influences nephron segmentation after gastrulation {#s2-6}
------------------------------------------------------------------------------------------------

Since we found that *ptger2a* and *ptger4a* transcripts were expressed within renal progenitors beginning as early as the 12 ss, we hypothesized that prostaglandin signaling may begin to operate at that time period to influence pronephros segmentation. To test this, we treated WT embryos with either the nonselective Cox1/2 antagonist indomethacin (30 µM) to block Ptgs activity or the agonist dmPGE~2~ (100 µM) from the 12 ss through to the 24 hpf time point, and then performed WISH to assess the pronephros segments. Indomethacin treatment during this time window elicited an expansion of the DE domain and a reduction of the DL similar to that seen from indomethacin treatments from 4 hpf to 24 hpf ([Figure 5A](#fig5){ref-type="fig"}). Further, dmPGE~2~ treatment from the 12 ss to 24 hpf was sufficient to induce an expansion of the PST and a reduction of the DL ([Figure 5B](#fig5){ref-type="fig"}). Absolute measurements of these segments changes in indomethacin and dmPGE~2~ treated embryos revealed that they were significant compared to controls and were similar to pharmacological exposures performed between the 4 hpf and 24 hpf time period ([Figure 5C](#fig5){ref-type="fig"}). Interestingly, we also found that treatments with either of two different Ptger2 small molecule antagonists, PF04418948 or AH6809, from the 12 ss to 24 hpf was likewise sufficient to induce a statistically significant expansion of the DE segment and reduction of the DL segment compared to WT controls ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). These data identify the 12 ss through the 24 hpf time period as the critical interval when pronephros progenitors require PGE~2~ signaling for normal segment development.10.7554/eLife.17551.022Figure 5.Prostaglandin signaling influences nephron patterning after gastrulation.Embryos were treated with 0.3% DMSO or 1% DMSO vehicle control, (**A**) 30 μM indomethacin, or (**B**) 100 μM dmPGE~2~ from the 12 ss to the 28 ss and stained for the PST (*trpm7*), DE (*slc12a1*), and DL (*slc12a3*) (purple) using WISH at the 28 ss stage. Black bars indicate segment gene expression domain. Red scale bar, 70 µm. (**C**) The PST, DE, and DL domains were measured in microns (n = 5 for each control and experimental group). Data are represented as ± SD, ANOVA used to compare samples, \*p\<0.01, \*\*p\<0.05, where n.s. indicates not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.022](10.7554/eLife.17551.022)10.7554/eLife.17551.023Figure 5---figure supplement 1.Inhibiting Ptger2a after gastrulation induces an expansion of the distal early and a restriction of the distal late segment.(**A**) Embryos were treated with 0.3% DMSO, 3 μM AH6809, or 3 μM PF04418948 from the 12 ss to the 24 hpf, then fixed and stained for the DE (*slc12a1*) and DL (*slc12a3*) using WISH at the 24 hpf stage. Black bars indicate segment gene expression domain. Red scale bar, 70 µm. The (**B**) DE and (**C**) DL domains were measured in microns (n = 5 for each control and experimental group). Data are represented as ± SD, ANOVA used to compare samples, \*p\<0.01, where n.s. indicates not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.023](10.7554/eLife.17551.023)

Cox expression and PGE~2~ levels affect renal progenitor transcription factor domains {#s2-7}
-------------------------------------------------------------------------------------

Several transcription factors are known to be critical for proper tubule segment patterning during zebrafish pronephros development. Some of these include: *sim1a*, which is expressed throughout both the PCT and PST, and is essential for PST fate ([@bib7]); *irx3b*, which is expressed throughout both the PST and DE, and is essential for DE segment fate ([@bib62]; [@bib42]); and *mecom*, which is expressed dynamically along the renal progenitor field, ultimately becoming restricted to the DL domain where it is essential for normal formation of this segment ([@bib34]). Given these genes' respective roles in segment ontogeny, we hypothesized that PGE~2~ signaling affects renal progenitor fate by modulating the expression domains of one or more of these crucial factors. To investigate this, WT embryos were treated with either a control vehicle DMSO, dmPGE~2~, or indomethacin between the 4 hpf stage and the 20 ss, and then the spatial distribution of *sim1a*, *irx3b,* or *mecom* transcripts in the IM renal progenitors was assessed by WISH ([Figure 6](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}).10.7554/eLife.17551.024Figure 6.Prostaglandin signaling modulates key nephrogenesis transcription factors.(**A**) Embryos were treated with a 1% DMSO control, dmPGE~2~ at 100 μM, or indomethacin at 30 μM from 4 hpf to the 20 ss. WISH was used to stain for the transcription factors *sim1a*, *mecom*, and *irx3b* (purple) and the somites (red) at the 20 ss stage. Black bars indicate segment gene expression domain. Red scale bar, 70 µm. (**B**) The *sim1a, mecom* and *irx3b* domains were measured in microns (n = 5 for each control and experimental group). Data are represented as ± SD, ANOVA used to compare samples, \*p\<0.01, where n.s. indicates not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.024](10.7554/eLife.17551.024)10.7554/eLife.17551.025Figure 6---figure supplement 1.Prostaglandin signaling alters the expression of transcription factors necessary for normal patterning of the nephron.(**A**) Embryos were treated with 1% DMSO, 100 μM dmPGE~2~, and 30 μM indomethacin from 4 hpf to the 20 ss and then stained for *sim1a*, *mecom*, and *irx3b* using WISH. Embryos were categorized into phenotypes using the 1% DMSO treated embryo domains as a reference point, along with juxtaposed somites, to determine changes in expression. At least 15 embryos were used for each control and experimental group. Data are represented as ± SD significant by t test comparing each drug treatment to the corresponding DMSO control group, \*p\<0.05, \*\*\*\*p\<0.00005, \*\*\*\*\*p\<0.000005, where n.s. indicates not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.025](10.7554/eLife.17551.025)

Interestingly, we found that dmPGE~2~ treatment led to a significant expansion of the *sim1a* and *irx3b* domains, along with a significant reduction of the *mecom* domain, in the majority of embryos ([Figure 6A,B](#fig6){ref-type="fig"}). These alterations are consistent with the observation that dmPGE~2~ expands the PST segment and restricts the DL ([Figure 2](#fig2){ref-type="fig"}). Further, we found that indomethacin treatment led to no significant change in the *sim1a* domain, while the *irx3b* domain was significantly increased in absolute length and the *mecom* domain was significantly reduced in length ([Figure 6A,B](#fig6){ref-type="fig"}). These alterations are in keeping with the prior observations that nonselective Cox inhibition with indomethacin, selective Cox1 or Cox2 inhibitors, as well as knockdown or inhibition of Ptger2a and Ptger4a expanded the DE segment and reduced the DL ([Figures 3](#fig3){ref-type="fig"},[4](#fig4){ref-type="fig"}). In summary, these data suggest that PGE~2~ signaling influences segment programs in part by affecting the expression of *sim1a*, *irx3b*, and *mecom*, either directly or indirectly, to mediate nephron segmentation.

Cox activity and PGE~2~ act upstream of *irx3b* and *sim1a* {#s2-8}
-----------------------------------------------------------

Next, we tested the epistatic relationships between prostaglandin signaling and the essential transcription factors *irx3b*, *mecom*, and *sim1a*. As knockdown of *irx3b* results in loss of the DE segment ([@bib62]), we exposed *irx3b* morphants to the Ptgs1 (Cox1) selective inhibitor SC-560 to test how the combined deficiency of *irx3b* and prostaglandin synthesis would impact the process of DE development during nephron segmentation. Embryos that were treated with SC-560 concomitant with *irx3b* deficiency failed to form a DE segment, similar to *irx3b* deficiency alone ([Figure 7A,B](#fig7){ref-type="fig"}). Taken together with the observation that indomethacin treatment was sufficient to expand the *irx3b* expression domain, this result is consistent with the conclusion that prostaglandin signaling occurs upstream of *irx3b* to regulate DE segment development.10.7554/eLife.17551.026Figure 7.Prostaglandin signaling acts upstream of the transcription factors *sim1a* and *irx3b*.(**A**) Embryos were microinjected with the *irx3b MO* and treated with 0.5% DMSO or 50 µM SC-560 from 4 hpf to 24 hpf and stained for the DE using WISH. WT control embryos were also treated with 0.5% DMSO and 50 µM SC-560. (**B**) The DE (*slc12a1*) (purple) was stained for using WISH and quantified in triplicate, with at least 20 embryos per control and experimental group, by observing for the presence of the DE segment at the 24 hpf stage. Black bars indicate segment gene expression domain. Red scale bar, 70 µm. (**C**) Embryos were microinjected with the *sim1a MO* then treated with either 1% DMSO or 100 µM dmPGE~2~ from 4 hpf to 24 hpf. 1% DMSO and 100 µM dmPGE~2~ was also applied to WT control embryos from 4 hpf to 24 hpf. The PST (purple) and somites (red) were then stained for using WISH. (**D**) Quantification was undertaken in triplicate based on the presence of a PST or lack thereof, with at least 20 embryos per control and experimental group. Data are represented as ± SD, with t tests comparing each drug treatment to the corresponding DMSO control group, where n.s. indicates not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.026](10.7554/eLife.17551.026)10.7554/eLife.17551.027Figure 7---figure supplement 1.Overexpression of *mecom* cRNA failed to rescue the distal late segment in indomethacin treated embryos.(**A**) Embryos were microinjected with 70 pg of *mecom* cRNA then treated with either 0.3% DMSO or 30 µM indomethacin from 4 hpf to 24 hpf. Embryos were then stained for the DL (*slc12a3*) (purple) and the somites (red) using WISH at the 24 hpf stage. Black bars indicate segment gene expression domain. Red scale bar, 70 µm. (**B**) The DL was quantified in triplicate with at least 20 embryos per control and experimental group by categorizing embryos into phenotypes determined by somites parallel to segment expression. Data are represented as ± SD, significant by t test comparing each drug treatment to the corresponding DMSO control group, \*\*\*p\<0.0005.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.027](10.7554/eLife.17551.027)10.7554/eLife.17551.028Figure 7---figure supplement 2.Prostaglandin treatment shifts the distal early and restricts the distal late in *sim1a* morphants.(**A**) Embryos were microinjected with the *sim1a* MO and treated with 100 µM dmPGE~2~ or 1% DMSO from 4 hpf to 24 hpf. WISH was then used to label for the PCT (*slc20a1a*), DE (*slc12a1*), and DL (*slc12a3*) (purple) and the somites (*smyhc1*) (red) at the 24 hpf stage. Black bars indicate segment gene expression domain. Red scale bar, 70 µm. (**B**) Segments were quantified in triplicate with at least 20 embryos per control and experimental group. Data are represented as ± SD, significant by t test comparing each drug treatment to the corresponding DMSO control group, \*p\<0.05, \*\*p\<0.005, \*\*\*p\<0.0005, where n.s. indicates not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.028](10.7554/eLife.17551.028)

As we observed that the domain of *mecom* expression in renal progenitors is restricted when prostaglandin production was blocked with indomethacin ([Figure 6](#fig6){ref-type="fig"}), and that *mecom* deficiency in turn is associated with a reduced DL, we next explored whether restoration of *mecom* would be sufficient to rescue DL segment development in the absence of normal prostaglandin synthesis. To test this, *mecom* capped mRNA was synthesized and microinjected into 1-cell stage embryos, which were then treated with indomethacin or DMSO control as previously described ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). Overexpression of *mecom* at dosages ranging from 14--70 pg, in either the experimental or vehicle control group, was not sufficient to alter DL segment fate ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}, data not shown). At higher dosages of *mecom* cRNA, embryos were dysmorphic, which has been reported previously ([@bib34]), precluding further examination with this approach. Despite these negative results, the alterations in the *mecom* expression domain in indomethacin treated embryos suggest that prostaglandin synthesis likely acts upstream of *mecom* to influence DL segment development.

Finally, we explored the relationship between *sim1a* and PGE~2~ signaling. Previous work from our laboratory has demonstrated that *sim1a* overexpression is sufficient to expand the PST segment ([@bib7]). In light of this, along with our present finding that exogenous PGE~2~ treatment induces both an expanded PST segment and expanded *sim1a* domain, we hypothesized that the gain of function prostaglandin phenotype was reliant on *sim1a* for the alteration in PST fate. To test this, embryos were microinjected at the 1-cell stage with a *sim1a* ([@bib7]), then incubated in either DMSO control or treated with dmPGE~2~ between 4 and 24 hpf. We found that knockdown of *sim1a* concomitant with dmPGE2 treatment led to an abrogation of the PST segment, similar to *sim1a* deficiency alone ([Figure 7C,D](#fig7){ref-type="fig"}, [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). These results are consistent with the conclusion that *sim1a* acts downstream of PGE~2~ signaling in the context of exogenous treatment to drive expansion of the PST segment.

Discussion {#s3}
==========

Understanding the genetic factors necessary to generate different cell types is an important aspect of developmental biology. Knowledge of these, along with an appreciation of the modulators that can impact the genesis of cell lineages, including their related morphogenetic processes, provides powerful insights relevant to congenital defects, disease pathology, regeneration and *in vitro* reprogramming ([@bib42]). Relevant to the present report, the kidney organ has many associated congenital diseases, and there is an escalating incidence of acute and chronic renal diseases for which a deeper understanding of mesodermal developmental processes has many possible applications ([@bib44]).

In this study, we uncovered evidence of a role for prostaglandin signaling in nephron segment formation during embryonic zebrafish development. Prostaglandins have diverse and potent biological actions ([@bib16]), however, their effects on developing tissues including stem cells have only recently begun to be appreciated ([@bib48]; [@bib21]; [@bib47]). By conducting a chemical genetic screen in zebrafish embryos to identify factors that affect nephron development, we found that several prostaglandin moieties were capable of modulating proximal-distal segmentation, first validating PGB~2~ and then subsequently identifying PGE~2~ as well ([Figure 8](#fig8){ref-type="fig"}). Specifically, we demonstrated that the addition of exogenous PGE~2~ or PGB~2~ was sufficient to increase PST segment size in a dosage-dependent manner. Using several chemical and genetic approaches, we demonstrated that abrogated prostaglandin activity alters formation of the DE and DL nephron tubule segments, where deficiencies in *ptgs1*, *ptgs2a*, or the PGE~2~ receptors encoded by *ptger2a* and *ptger4a* led to an expanded DE and reduced DL segment, and that PGE~2~ could specifically rescue the loss of Ptgs1 or Ptgs2a. We also determined that changes in Cox-mediated prostaglandin synthesis or PGE~2~ correlated with alterations in the expression domains of essential segmentation transcription factors in renal progenitors, suggesting some mechanisms by which prostaglandin signaling acts to influence segmentation ([Figure 8](#fig8){ref-type="fig"}). Understanding how these changes relate with morphogenesis involving cellular dynamics (e.g. proliferation, turnover) or even migration of the renal progenitors will be important aspects for future investigations.10.7554/eLife.17551.029Figure 8.The role of prostaglandin signaling during zebrafish nephrogenesis.(**A**) PGE~2~ is generated by the Ptgs1 and Ptgs2a enzymes, which interact with the Ptger2a and Ptger4a receptors to define the boundaries of the DE by negatively regulating the domain of *irx3b* expression and promoting DL identity. (**B**) Exogenous prostaglandin treatment promotes PST identity, partly by regulating *sim1a* expression, and these alterations occur at the expense of the DL segment. Not depicted: exogenous PGE~2~ is also associated with an increased *irx3b* domain, which correlates with the shifted posterior location of the DE in the context of PST expansion. Further, in both (**A**) and (**B**), the *mecom* expression domain is reduced in length, which is likely part of the mechanism underlying the DL segment size reduction in these cases.**DOI:** [http://dx.doi.org/10.7554/eLife.17551.029](10.7554/eLife.17551.029)

Previous studies have shown that PGE~2~ is among the major prostanoids produced during the first day of zebrafish embryogenesis ([@bib2], [@bib3]). Based on this and our ability to rescue Cox1/2 deficiency with dmPGE~2~ treatment alone, we theorize that PGE~2~ is the central endogenous signaling component that affects pronephros development. Further, the localization of *ptger2a* and *ptger4a* expression in renal progenitors suggests that these cells directly receive and respond to prostaglandin signals. Since prostaglandins are known to act in an autocrine or paracrine fashion with short half-lives, we speculate that the IM renal precursors themselves or nearby tissues like the paraxial mesoderm are the local source(s) of prostanoids. Based on the results of several epistasis experiments, we currently hypothesize that PGE~2~ signaling restricts the DE fate in part by negatively regulating *irx3b*, and that elevated PGE~2~ levels expand the PST segment through positive regulation of *sim1a*, though future studies are needed to delineate if these interactions are direct or indirect ([Figure 8](#fig8){ref-type="fig"}). Finally, our data repository of small molecules that affect pronephros ontogeny will provide a useful starting point for future studies by our lab and others to study nephrogenesis further in zebrafish or in other vertebrates ([Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}).

Mechanisms of prostaglandin signaling during nephrogenesis {#s3-1}
----------------------------------------------------------

Early genetic studies that interrogated the effect of disrupting prostaglandin synthesis in homozygous mutant COX-1 or COX-2 mice did not report observing overt abnormalities at birth ([@bib31]; [@bib43]; [@bib35]). Similarly, knockouts of other biosynthesis enzymes and the prostaglandin receptors had normal neonatal phenotypes ([@bib57]; [@bib28], [@bib29]). Intriguingly, however, mice lacking COX-2 exhibit postnatal kidney pathologies associated with neonatal fatality, including nephron hypoplasia and atrophy, impaired cortical growth, and even cyst formation in multiple nephron segments---phenotypes suggestive of significant disruptions in renal ontogeny ([@bib10]; [@bib43]; [@bib35]). These observations were not further explored until recently, however, where COX-2 gene dosage and pharmacological inhibition were linked to renal defects in glomerular size, such that COX-2^+/-^ mice were found to exhibit kidney insufficiency ([@bib55]). In alignment with these data, exposure to COX inhibitors like indomethacin during human development is associated with renal failure, where the histological aspects include small glomeruli and microcystic lesions among other defects ([@bib20]; [@bib59]; [@bib26]).

In light of these recent observations along with our findings, we propose that prostaglandin signaling, likely through PGE~2~, has critical roles in nephrogenesis, which warrant further investigation. However, there are significant challenges of studying nephron formation in mammalian models due to their *in utero* development, and while metanephric organ culture has been informative for branding morphogenesis studies, it is not conducive to studying nephrogenesis. Therefore, the zebrafish pronephric model provides an alternative for continued genetic dissection of the cellular and molecular effects in nephron development due to alterations in prostaglandin levels. Based on the requirement for PGE~2~ during pronephros development, it will be interesting to explore its effects on renal progenitors in other stages of zebrafish kidney ontogeny, and during new nephron formation and epithelial regeneration events in adults as well ([@bib40]). In the near future, emergent organoid technologies will likely provide a complementary *in vitro* experimental system to probe the mechanisms of prostaglandin signaling in mammalian nephrogenesis ([@bib4]).

Further, while our report documents an essential role for PGE~2~ signaling during nephron formation, more work needs to be done to further understand the genetic networks that affect segment fate. For example, we have previously shown that RA acts as a morphogen in the zebrafish, and that a gradient of RA induces proximalization of the impending pronephros ([@bib63]; [@bib62]). It is intriguing to speculate that a prostaglandin signaling gradient, where PGE~2~ acts as a morphogen, as recently proposed ([@bib47]), may articulate with RA to balance proximo-distal specification of the renal progenitors, though further studies are needed to interrogate this possibility. In addition, prostaglandins have been shown to initiate transcription through either interacting with cognate Ptger (EP) receptors or alternatively, passing through the cell membrane and binding with peroxisome proliferator-activated receptors (PPARs) ([@bib23]; [@bib1]). Interestingly, PPARs can heterodimerize with Retinoid X Receptors (RXRs), a nuclear receptor for RA ([@bib23]; [@bib1]). Also, it has been shown that different prostaglandins can interact interchangeably, at the right concentration, with the various Ptger receptors ([@bib58]). This might explain why different prostaglandins could induce an expansion of the PST.

Understanding the broader roles of PGE~2~ signaling in development {#s3-2}
------------------------------------------------------------------

Prostaglandins have only just started to become recognized as important factors and determinants of cell fate decisions and growth during development. These new roles for prostaglandins have been revealed in part through a study showing that PGE~2~ activity has a conserved function to expand the domain of HSCs in development and enhance their ability to home to the bone marrow in transplants ([@bib48]). PGE~2~ is currently in phase two clinical trials for increasing the efficiency of bone marrow transplants ([@bib24]). Furthermore, PGE~2~ was shown to be a regulator of bipotential endoderm cell fate decisions in development for zebrafish and mouse endodermal cells ([@bib47]). Curiously, it was also shown that PGE~2~ activity later in organ formation induced proliferation of both the liver and pancreas buds. This change in the function of PGE~2~ is explained by the spatial and temporal expression of *ptger2a* and *ptger4a,* where blocking *ptger2a* promoted liver versus pancreas specification and blocking *ptger4a* promoted the outgrowth of the liver and pancreas buds. These cornerstone studies, along with the present report, give credence to the notion that PGE~2~ is a key regulator of progenitor populations during embryogenesis and set the stage for further inquiry into how prostaglandin signaling affects developing cell populations. As more knowledge comes to light about how PGE~2~ and other prostaglandins influence ontogeny, they are likely to become an increasingly intriguing option for clinical therapeutic applications.

Materials and methods {#s4}
=====================

Zebrafish husbandry {#s4-1}
-------------------

Zebrafish were cared for and maintained in the Center for Zebrafish Research at the University of Notre Dame using experiments approved under protocol 16--025. Adult Tübingen strain fish were used for these studies, and their offspring were staged as described ([@bib27]).

Chemical genetic screen and other chemical treatments {#s4-2}
-----------------------------------------------------

Zebrafish wild-type (WT) embryos were arrayed and treated with small molecules using the ICCB Known Bioactives Library as described ([@bib50]). Zebrafish embryos were staged at 2 hpf, then at least 30 fertilized embryos were arrayed into the chambers of 24-well plates and incubated at 28°С in E3 media until just prior to 4 hpf. Working stocks of small molecules were stored at −80°С, then dissolved in 100% DMSO to make 10 mM concentrations ([@bib32]). For drug exposure, the E3 media was completely drawn off the embryos using a glass transfer pipet and the appropriate solution of DMSO, PGB~2~, dmPGE~2~, indomethacin, SC-560, NS-398, AH6809, or PF04418948 was applied at a discrete development time point (eg 4 hpf or 12 ss) (American Bioanalytical, Enzo Life Sciences, Santa Cruz) ([@bib48]; [@bib15]; [@bib25]). Embryos were raised to the 20 ss or 24 hpf, washed three times with E3, then fixed in 4% paraformaldehyde. For rescue of prostaglandin activity*, ptgs1 or ptgs2a* deficient embryos were generated, and cohorts of approximately 30 embryos were arrayed in 24-well plates with E3, then placed in a 28°С incubator until 4 hpf. E3 was then completely drawn off the wells using a glass transfer pipet and a 50 µM concentration of dmPGE~2~ was applied. The embryos were placed into a 28°С incubator, raised until 24 hpf, washed three times with E3, and fixed as previously described.

Embryo staining for WISH, o-dianisidine, and image acquisition {#s4-3}
--------------------------------------------------------------

WISH was conducted as described ([@bib5]). RNA probes were digoxigenin or fluorescein labeled and generated by *in vitro* transcription using plasmid templates as described ([@bib63]; [@bib62]; [@bib32]; [@bib34]; [@bib7]). For o-dianisidine staining, embryos were treated with 1% DMSO, 50 µM dmPGE~2~, or 30 µM, were allowed to develop until 48 hpf and o-dianisidine staining was performed ([@bib60]). Images were taken using a Nikon Eclipse Ni with a DS-Fi2 camera. Figures were assembled using Adobe Photoshop CS5.

Morpholino knockdown and RT-PCR {#s4-4}
-------------------------------

Antisense morpholino oligonucleotides (MOs) were purchased from Gene Tools, LLC. MOs were solubilized in DNase/RNase free water to create 4 mM stocks and stored at −20°С. WT embryos were collected after fertilization, injected with approximately 1 nl of diluted MO at the 1-cell stage and then placed in a 28°С incubator until the desired stage. MO sequences and dosages used were: *irx3b* 5\'-ATAGCCTAGCTGCGGGAGAGACATG-3\', 1 ng ([@bib62]); *ptger2a* MO1 5\'-GATGTTGGCATGTTTGAGAGCATGC-3\', 3 ng ([@bib48]); *ptger2a* MO2 5\'-ACTGTCAATACAGGTCCCATTTTC-3\', 1.6 ng ([@bib48]); *ptger2a* MO3 splice 5\'-CAATAAATCTTACTATTAACGGCAG-3\', 3 ng; *ptger2a* MO4 splice 5\'-ATGTACACACGGATCTG-AAGAGAAG-3\', 3 ng; *ptger4a* MO1 5\'-CGCGCTGGAGGTCTGGAG-ATCGCGC-3\', 3 ng ([@bib48]); *ptger4a* MO2 5\'-CACGGTGGGCTCCATGCTGCTGCTG-3\', 3 ng ([@bib3]); *ptger4a* MO3 splice 5\'-CCTGGAACTTACAACAAGCGGGATT-3\', 3 ng; *ptger4a* MO4 splice 5\'-TGAGAAACA-CCTGGACCTGCCAGAA-3\', 3 ng; *ptgs1* MO 5\'-TCAGCAAAAAGTTACACTCTCTCAT-3', 3 ng ([@bib48]); *ptgs2a* MO 5\'-AACCAGTTTATTCATTCCAGAAGTG-3\', 3 ng ([@bib22]); *ptgs1* MO splice 5\'-AACTTTCATTGCTC-ACCTCTCATTG-3\', 2 ng; *ptgs2a* MO splice 5\'-ATTCAACTTA-CACAACAGGATATAG-3\', 2 ng ([@bib65]), *sim1a* MO 5\'-TCGACTTCTCCTTCATGCTCTACGG-3\', 1 ng ([@bib7]). To assess knockdown efficacy, RT-PCR and sequence analysis was performed as previously described ([@bib38]) and using the following primers, where uppercase letters indicate location in an exon and lowercase indicates primer location in an intron: ptgs1-F1 5\'-TTTATTTATTTGCAGCTTTTTCTT-3\'; ptgs1-R1 5\'-CAGTGTTTGATGAAGTCGGGCTTTC-3\'; ptgs2a-F1 5\'-CTGAGCTTCTCACACGCATCAAAT-3\'; ptgs2a-R1 5\'-GGCGAAGAAAGCAAACATGAGACT-3\'; ptger2a-F1 5\'-AGACCGAGCGTATGCCAATGT- 3\'; ptger2a-R4 5\'-caggagggctaataattcagactt-3\'; ptger2a-F3 5\'-ctgtttcagtgatcagtttgt-3\'; ptger2a-R7 5\'-CCGCAGAGCTATGAGATCAGTC-3\'; ptger2a-R8 5\'-GCTGAGGATGATGAACACCAAG-3\'; ptger4a-F3 5\'-ATGGTCATCCTGTTGATCGCC-3\'; ptger4a-R2 5\'-aatgagagtcctggaacttac-3\'; ptger4a-F5 5\'-gggtgtagtcatttatgttgagca-3\'; ptger4a-R5 5\'-CAGGACCGCTTTACGCAGTAAG-3\'.

Quantification of phenotypes, segment measurements, imaging and statistical analysis {#s4-5}
------------------------------------------------------------------------------------

Gene domains were assessed with respect to somite boundaries to assess pattern formation ([@bib63]). Segment domains were analyzed and counted in triplicate with at least 15 embryos per replicate. To measure absolute segment lengths, images were taken of at least five representative embryos. Images were collected using a Nikon Eclipse Ni with a DS-Fi2 camera and measurements performed with Nikon Elements Software. The average was generated and standard deviation (± SD) calculated, and unpaired (student) t-tests were performed to compare experimental groups with the corresponding wild-type control group. In cases where there were several percentage categories of phenotypes, the statistical comparison was performed between like categories, e.g. percentage increased were compared between control and each experimental treatment. In addition, ANOVA tests were performed to assess statistical significance in the context of comparing multiple samples.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Prostaglandin signaling regulates nephron segment patterning of renal progenitors during vertebrate kidney development\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor (Tanya Whitfield) and Sean Morrison as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Dirk Meyer (Reviewer \#1); Lilianna Solnica-Krezel (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This is an interesting study on that addresses the factors that influence cell fate decisions in the developing vertebrate kidney, using the embryonic zebrafish pronephros as a model system. The authors have used a chemical genetic approach to identify prostaglandins as mediators that influence cell fate choice during development of the proximal and distal nephron segments. Results from the pharmacological screen have been validated through the use of morpholino-based gene knockdown to inhibit prostaglandin synthesis. The authors propose that the prostaglandin pathway acts upstream of the previously-identified transcriptional regulators Irx3b and Sim1a in the developing pronephros. The reviewers and editors agreed that the work was interesting and potentially significant. However, they also had some concerns that should be addressed to strengthen the manuscript, as outlined below.

Essential revisions:

1\) Title: as suggested by reviewer 1, please change the word \'vertebrate\' to \'zebrafish\'. (Please note, however, that it is not essential to extend the work to other vertebrate species or different stages of kidney development.)

2\) Given the known interactions between prostaglandin and other pathways such as Wnt signalling, there are concerns over the relevance of the phenotypes resulting from long-term treatment (4-22 hpf) with PG agonists for a nephron-specific patterning role of prostaglandins. These concerns are exacerbated by the rather mild nephric phenotypes described for prostaglandin pathway morphants. The option of indirect phenotypes therefore needs further discussion. In addition, experiments with later onset of agonist treatment are also required to exclude interference with general early embryonic patterning, for example by Wnt signalling. See comments from reviewer 1.

3\) Following discussion between the reviewers, it was felt that a full analysis of any connection with Wnt signalling was not essential, but might be an interesting extension of the work in the future.

4\) Measurements. There were concerns over the measurements and quantitation of the data, in particular, in the way that the extent of expression domains was measured (by a horizontal bar in terms of somite length, vs the actual length of the curved domain of gene expression shown). It was felt that more accurate measurements should be provided. In addition, n numbers should always accompany percentage values, wherever shown.

5\) Effects on surrounding tissues. Please provide some assessment of the extent to which surrounding tissues are affected by the treatments shown.

6\) The text needs tightening up in places, especially with reference to the distinction between PGs in general and PGE2 (see comments from reviewer 2).

7\) For the experiments using morpholinos, it is important that these were done as rigorously as possible. Further supporting evidence is needed here (see comments from reviewer 3).

*Reviewer \#1:*

In their manuscript Poureetezadi et al. use the zebrafish pronephros as a model to study functions of the prostaglandin pathway on nephron formation and patterning. Prostaglandins and in particular PGE2 have well documented functions in postnatal mammalian kidney development and renal physiology. In contrast, very little is known about activities in early kidney formation, mainly as genetic studies in mouse provided no major evidence for such requirements. In a screen for small compounds affecting zebrafish pronephron formation Poureetezadi et al. identified several prostaglandin agonists as agents causing caudally shifted or expanded tubule segments upon treatment of embryos between 4-24hpf. Detailed pharmacological analyses confirmed dose-dependent activities of PGE2 and the PGE2-derived PGB2 in tubule segmentation, and provided hints for a requirement of prostaglandin synthesizing enzymes COX1/2 and the PGE2 receptors Ptger2a/4a in the precise positioning of caudal segments. The pharmacological loss-of-function data were further confirmed by knockdown studies using morpholinos that supposedly prevent expression of COX1/2 and Ptger2a/4a proteins. Further, the authors show that nephric phenotypes seen after early embryonic interference with prostaglandin signaling correlate with changed expression of key transcriptional regulators of tubule segmentation and they provided evidence for a genetic role of prostaglandin signaling upstream of these factors. This interesting work is the first one demonstrating prostaglandin activities in nephric tubule patterning.

Unfortunately, the authors had addressed neither the underlying molecular mechanism nor the relevance for other vertebrate model systems or the metanephric kidney.

As pointed out by the authors, prostaglandins only recently became recognized as developmentally import fate determinants. In this context interference with canonical wnt-signaling had been identified as one of the most critical prostaglandin activities. Considering the importance of Wnt-signaling in kidney formation and patterning it is surprising that this connection had not been further analyzed.

The word \'vertebrate\' in the title is not justified as the zebrafish is the only vertebrate that had been analyzed. Slattery et al. (2016) recently suggested a role of COX2 not only in postnatal but also in embryonic metanephric kidney development. While these mouse data support a possibly conserved requirement for prostaglandins, it should be noted that the phenotypic analyses of COX2 mutants was restricted to the glomerulus and no tubule data were provided.

The authors suggest a direct connection between the proposed nephron specific expression of ptger2a/4a ([Figure 4](#fig4){ref-type="fig"}---figure supplement.4) and the nephric loss and gain of function phenotypes. Expression of prostaglandin pathways components is not well documented and the experimental settings leave space for various alternative explanations. The images shown in [Figure 4](#fig4){ref-type="fig"}---figure supplement.4 suggest a restricted expression of ptger2a/4a in proximal tubule of 12-24ss embryos. In case of a direct function, pharmacological treatments starting at 12ss rather than at 4hpf should be sufficient to induce relevant gain and loss of function phenotypes. Additional data should be provided to confirm nephron specificity and to give details on the posterior-anterior extent of ptger2a/4a expression (for example sections and co-stains with nephric markers). Further, studies should be performed to determine the critical time-window of prostaglandin responsiveness.

*Reviewer \#2:*

In the manuscript entitled \"Prostaglandin signaling regulates nephron segment patterning of renal progenitors during vertebrate kidney development\" by Poureetezadi et al., stemming from a chemical screening approach, the authors uncover a role for prostaglandin activity which impacts distal vs. proximal segment development of the pronephric tubules in the kidney. Specifically they found that exposure to prostaglandin agonists expanded the proximal segment (slc20a1a+) lineage and inhibited distal fate (slc12a1a+). In contrast inhibition of PG synthesis altered the distribution of specific distal fates. The authors also identified downstream consequences on key segment associated genes (irx3b and sim1a) that appeared to be influenced, directly or indirectly by PG modulation. The data presented throughout the paper strongly support the authors claims, however, descriptions of prostaglandin synthesis and signaling cascades are over-simplified, and general claims are made for \"prostaglandins\" when only PGE2-specific components are thoroughly investigated. As several types of prostaglandins were isolated in the screen, which can act in methods different from that investigated here (thromboxane receptor and PPARg), more precise language and a rationale for selecting PGE2 (not hit in the screen) would aid the reader. Similarly, while the data is nicely presented and logically organized to support the authors conclusions, the paper would benefit from addition of quantitative evaluations to aid appreciation by those outside of the field.

1\) The authors over-simplify prostaglandin synthesis and signaling pathways, applying terminology and biological function relevant to PGE2 under the broad headline of \"prostaglandins\". This occurs as early as [Figure 1](#fig1){ref-type="fig"}, where they identify PGD2, PGA2, PGB2, and PGJ2 in the screen, which are known to stimulate thromboxane receptors (PGA2, B2) and PPARg (PGJ2), yet follow PGE2 (not a hit) and its relevant machinery. Similarly, Ptges is the enzyme for prostaglandin E2 synthesis (hence the \"e\" in its name, not general secondary processing), and Ptgers are the receptors for PGE2, not all of the PGs. While PTGS inhibition (Cox enzymes), could indeed broadly impact PG synthesis, the rest is quite specific to PGE2 and should not be generalized in the text, particularly when the screen hit several other potential modifiers as relevant to kidney biogenesis. This is not to say the data for PGE2 modification is wrong, it is just over generalized to \"prostaglandins\" and as such could cause issues for future investigations.

2\) Given the independent signaling cascades associated with PGB2 and PGE2, it is surprising that exposure to both enzymes elicited the same biological effect. While receptor modulation is examined for 2 of the 4 PGE2 receptors, similar studies should be done in the context of exogenous PGE2 and PGB2 addition, as well as with the thromboxane receptors to confirm that addition of exogenous levels of each prostanoid doesn\'t cause errant signaling.

3\) The doses utilized for dmPGE2 and Indomethacin are substantially higher than that found in other zebrafish or mouse papers, and well above physiological concentrations in humans. While the embryos appear grossly normal in whole mount images, it is important to document that alterations in kidney associated expression patterns are not simply due to gross morphological development issues or off target effects. Assessment of vascular markers by in situ or with a reporter line (Grosser et al) should be a quick way to test toxicity; receptor blocking analysis should confirm specificity.

4\) While the overall conclusions seem well supported by the data shown, to make the paper more accessible to a general audience, the authors should use a more precise way to quantify the alterations in expression observed, or at least confirm the relevant ones, using ImageJ and/or a reporter line. The assays are currently very observational (with straight bars correlated with expression drawn on curvy embryos) and it is unclear how definitive statements like \"50% reduction\" are made when no quantification is shown.

*Reviewer \#3:*

Starting with a chemical screen in developing zebrafish embryos, the Wingert and collaborators, identify components of prostaglandin signaling pathway as regulators of proximo-distal patterning of developing kidney. Using treatments with the pathway agonists (dmPGE2, PGB2) or inhibitors, and antisense morpholino oligonucleotides to impair expression of the PG synthetizing enzymes and their receptors (Ptger2a, Ptger4a), the authors provide evidence that prostaglandin signaling limits distal segment formation while promoting the proximal pronephric fates, acting upstream of Irx3b and Sim1a transcription factors, which have been previously implicated in this process. This is a very interesting work that expands our appreciation of the roles of prostaglandin signaling in cell fate specification during vertebrate embryogenesis. These roles were difficult to discern in the murine model, but recent studies in mouse and human point to PG involvement in kidney development and function. The authors leverage the experimental strengths of the zebrafish model, in which prostaglandin signaling can be easily manipulated during kidney development and the resulting effects can be monitored.

Whereas the proposed conclusions are significant and would be of interest to the developmental biology and renal research communities, they are not sufficiently supported by the presented data. Addressing the following questions and concerns would significantly strengthen the manuscript and make it suitable for publication.

One of the major concerns about the current manuscript is that there are many quantifications presented but without sufficient experimental detail to evaluate their statistical or biological significance. For several experiments (e.g. treatment of antagonists), there is insufficient experimental detail to evaluate the results and their interpretation. The quantifications of the phenotypes (reduction or expansion) of segments in various experimental regimens is given throughout the manuscript as% of embryos with altered expression (expanded or reduced). This shows that the fraction of affected embryos increases in a dose dependent manner but does not address whether the expressivity (degree of reduction or expansion) of the phenotype is also dose dependent. This is important given the overall conclusion that prostaglandins regulate segment patterning.

Were the measurements carried in a blinded fashion?

The number of embryos in individual experiments showing% of phenotype should be provided.

For Indomethacin treated embryos, the authors conclude that they \"developed a 50% larger DE segment domain and a 20% smaller DL segment domain\" referring to [Figure 3](#fig3){ref-type="fig"} and its supplement. It is not clear where the data are presented on which this conclusion has been reached given that [Figure 3](#fig3){ref-type="fig"} shows fractions of affected embryos and not dimensions of pronephric segments in control and treated embryos. Such conclusions need to be supported by clearly presented morphometric data, with the method of measurement clearly described, as well as the numbers of analyzed embryos.

The authors conclude that the changes in the dimensions of the pronephros proximo-distal segments represent the specific effects of prostaglandin signaling. However, the possibility of broader effects of prostaglandin signaling on embryonic dimensions and thus indirectly on pronephros is not sufficiently addressed. In the Methods the authors state \"Gene domains were measured with respect to somite boundaries to assess pattern formation\". However, the somitic staining that should provide such a reference is not clear in most of the figures. Given that earlier reports implicated prostaglandin signaling in morphogenetic movements of gastrulation (Gasser et al., PNAS, 2002; Cha et al., Genes & Dev, 2006; Speirs et al., Development, 2011), this needs to be carefully analyzed. Anteroposterior dimensions of the treated embryos should be measured as well as the relative size of pronephric segments to the neighboring somites for a reviewer/reader to evaluate.

In experiments in which PG signaling was inhibited with various agents, it is not clear at what developmental stages was this done? Given the previous work implicating PG signaling in gastrulation movements the timing of the treatment is important. It would be also of interest to identify when during embryogenesis PG signaling is required for segment patterning and when it can affect it.

Injection into 1 cell stage embryos of translation and splicing morpholinos targeting ptgs1 (cox1) and ptgs2a (cox2) enzymes is reported to affect pronephros patterning. However, it has been previously reported that ptgs1 morpholino injections caused severe epiboly defects (Gasser et al., 2002). In this work the morpholino experiments are insufficiently described. There is no information on the dosage of morpholinos per embryos (only stock concentration is given in methods), no dose response, no experiments describing the degree of loss of function. Yet, the authors conclude \"these data indicate that endogenous levels of prostaglandins are critical for specification of the DE and DL segments\". This conclusion is given before dmPGE2 rescue experiments are described.

Similar lack of detail and controls is a concern for the experiments in which two genes encoding the prostaglandin receptors, ptger2a and ptger4a are targeted using morpholinos. There are no data on the effectiveness of these reagents to downregulate expression of these genes and encoded proteins, or to lower the levels of prostaglandins. Since in recent years, significant concerns have been raised about the specificity of morpholinos (e.g. Kok et al., Dev Cell, 2015), the sparse details and controls for the experiments presented raise concerns.

In epistasis experiments presented in [Figure 6A, B](#fig6){ref-type="fig"} it would be important to see the effect of SC-580 alone. From the perspective of the model of PG -- irx3b pathway proposed in [Figure 7A](#fig7){ref-type="fig"}, the effect of dmPGE2 treatment that affect PST and DL but do not affect DE are confusing.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Prostaglandin signaling regulates nephron segment patterning of renal progenitors during zebrafish kidney development\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Sean Morrison (Senior editor) and Tanya Whitfield (Reviewing editor).

The manuscript has been substantially improved and all reviewers\' comments have been addressed well. The additional experimental data help to strengthen and support the findings, and the writing is now clear and precise. Overall, this is a very interesting study and should be of wide interest.

One concern remains: the quantification has been improved but there was very little information about the statistical tests used for analysis of the data. t-tests are mentioned in the Materials and methods section, but these will not be suitable for analysis of some of the datasets, where there are multiple conditions and comparisons. Here, a test such as ANOVA, with appropriate post-test correction for multiple samples, would be preferred. Alternatively, the authors should clarify and justify the tests they have used. The tests that are used should be stated in each of the figure legends where appropriate, in addition to the statement in the Materials and methods.

10.7554/eLife.17551.031

Author response

*Essential revisions:*

*1) Title: as suggested by reviewer 1, please change the word \'vertebrate\' to \'zebrafish\'. (Please note, however, that it is not essential to extend the work to other vertebrate species or different stages of kidney development.)*

The authors agree and the recommended title change has been made.

*2) Given the known interactions between prostaglandin and other pathways such as Wnt signalling, there are concerns over the relevance of the phenotypes resulting from long-term treatment (4-22 hpf) with PG agonists for a nephron-specific patterning role of prostaglandins. These concerns are exacerbated by the rather mild nephric phenotypes described for prostaglandin pathway morphants. The option of indirect phenotypes therefore needs further discussion. In addition, experiments with later onset of agonist treatment are also required to exclude interference with general early embryonic patterning, for example by Wnt signalling. See comments from reviewer 1.*

We performed additional studies to address the time window when changes in PG levels affect nephron segment development. First, we treated embryos with either the antagonist indomethacin or agonist dmPGE~2~ starting at 12 ss with exposure lasting through to the 24 hpf time point. This indomethacin treatment elicited an expansion of the DE domain and reduction of the DL similar to that seen after the treatment lasting from 4 hpf to 24 hpf (new [Figure 5A](#fig5){ref-type="fig"}). dmPGE~2~ treatment between 12 ss and 24 hpf induced an expansion of the PST and a DL reduction similar to the long dmPGE~2~ exposure time (new [Figure 5B](#fig5){ref-type="fig"}). To quantify and further analyze these changes, we determined the absolute segment lengths and found the phenotypes following each PG alteration to be significant compared to controls, while the segment changes were indistinguishable from the corresponding drug exposure over the longer interval (new [Figure 5C](#fig5){ref-type="fig"}). Further, we found that treatment with Ptger2 antagonists from the 12 ss to 24 hpf was also sufficient to induce a statistically significant DE expansion and DL reduction (new [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), similar to the 4-24 hpf exposure ([Figure 4---figure supplement 6](#fig4s6){ref-type="fig"}; new [Figure 4---figure supplement 9](#fig4s9){ref-type="fig"}).

*3) Following discussion between the reviewers, it was felt that a full analysis of any connection with Wnt signalling was not essential, but might be an interesting extension of the work in the future.*

We have not pursued the connection to Wnt signaling in the current revision but agree that it will be an interesting extension for our future research.

*4) Measurements. There were concerns over the measurements and quantitation of the data, in particular, in the way that the extent of expression domains was measured (by a horizontal bar in terms of somite length, vs the actual length of the curved domain of gene expression shown). It was felt that more accurate measurements should be provided. In addition, n numbers should always accompany percentage values, wherever shown.*

We now provide absolute length measurements for all nephron segment phenotypes (Please see [Figure 2B](#fig2){ref-type="fig"}; [Figure 2---figure supplement 2E, F](#fig2s2){ref-type="fig"}; [Figure 3B, C](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1E, F](#fig3s1){ref-type="fig"}; [Figure 4---figure supplement 9](#fig4s9){ref-type="fig"}). Data involving phenotype penetrance and dosage responses have been moved to supplemental figures. We provide n values in either the graph or legend for all quantitations.

*5) Effects on surrounding tissues. Please provide some assessment of the extent to which surrounding tissues are affected by the treatments shown.*

We assessed surrounding tissues following PG agonist (dmPGE~2,~ 100 µM) and PG antagonist (indomethacin, 30 µM) exposure by whole mount in situ hybridization (as suggested by reviewer \#2), and also examined circulation within the vasculature. We did not observe differences *flk1* or *gata1* transcript expression at 24 hpf in embryos exposed to DMSO, dmPGE~2~ or indomethacin between 4 hpf and 24 hpf, indicating normal vascular and primitive blood development, respectively (new [Figure 2---figure supplement 4A, B](#fig2s4){ref-type="fig"}). This is consistent with a published study that reported effects of indomethacin at 40 µM, but normal development of the vasculature following indomethacin treatment at 25 µM (Cha, et al., 2005).

Next, we performed o-dianisidine (benzidene) staining in embryos treated with DMSO, dmPGE~2~ or indomethacin between 4 hpf and 24 hpf, which labels hemoglobinized erythrocytes and provides a sensitive assessment of defects in circulation or vascular integrity that can be undetected when using only live imaging with stereomicroscopy. Blood flow in these drug treated embryos was equivalent to wild-type control embryos through the 48-55 hpf stage, and we did not observe compromised vessel integrity or hematomas (e.g. bleeding, blood pooling) with o-dianisidine staining (new [Figure 2---figure supplement 4C](#fig2s4){ref-type="fig"}).

*6) The text needs tightening up in places, especially with reference to the distinction between PGs in general and PGE2 (see comments from reviewer 2).*

We have revised the manuscript extensively to address this weakness and to be more specific throughout.

*7) For the experiments using morpholinos, it is important that these were done as rigorously as possible. Further supporting evidence is needed here (see comments from reviewer 3).*

In the revision, we provide the data that morpholinos used to interfere with mRNA splicing of *ptgs1, ptgs2a, ptger2a* and *ptger4a* caused retention of intronic sequences that disrupt the coding sequence of each gene (new [Figure 4---figure supplement 10](#fig4s10){ref-type="fig"}). A full description can be found in the corresponding text and figure legend.

*Reviewer \#1:*

*\[...\] As pointed out by the authors, prostaglandins only recently became recognized as developmentally import fate determinants. In this context interference with canonical wnt-signaling had been identified as one of the most critical prostaglandin activities. Considering the importance of Wnt-signaling in kidney formation and patterning it is surprising that this connection had not been further analyzed.*

We agree that it would be interesting to delineate the relationship between prostaglandin signaling and canonical Wnt-signaling in relation to kidney development. However, we agree with the collective decision of the reviewers that this interrogation is beyond the scope of our present study.

*The word \'vertebrate\' in the title is not justified as the zebrafish is the only vertebrate that had been analyzed. Slattery et al. (2016) recently suggested a role of COX2 not only in postnatal but also in embryonic metanephric kidney development. While these mouse data support a possibly conserved requirement for prostaglandins, it should be noted that the phenotypic analyses of COX2 mutants was restricted to the glomerulus and no tubule data were provided.*

We have changed the title to \"Prostaglandin signaling regulates nephron segment patterning of renal progenitors during zebrafish kidney development\" to more specifically describe the context of the study.

*The authors suggest a direct connection between the proposed nephron specific expression of ptger2a/4a ([Figure 4---figure supplement 4](#fig4s4){ref-type="fig"}) and the nephric loss and gain of function phenotypes. Expression of prostaglandin pathways components is not well documented and the experimental settings leave space for various alternative explanations. The images shown in [Figure 4---figure supplement 4](#fig4s4){ref-type="fig"} suggest a restricted expression of ptger2a/4a in proximal tubule of 12-24ss embryos. In case of a direct function, pharmacological treatments starting at 12ss rather than at 4hpf should be sufficient to induce relevant gain and loss of function phenotypes.*

Pharmacological treatments have been performed between the 12 ss to 24 hpf for dmPgE2, indomethacin, and the Ptger2 antagonists. Treatment with either indomethacin or the Ptger antagonists between 12 ss and 24 hpf was sufficient to cause an expanded DE and reduced DL, as seen in treatments from 4 hpf to 24 hpf. dmPgE2 treatment between 12 ss and 24 hpf cause an equivalent expansion of the PST and a restriction of the DL as treatment between the 4 hpf to 24 hpf time. These findings are consistent with the notion that Ptger2a/4a act in zebrafish embryo renal progenitors between the 12 ss and 24 hpf to influence segment patterning. Descriptions of these studies have been added to the revised Results section, and the new data are located in new [Figure 5](#fig5){ref-type="fig"} and new [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}.

*Additional data should be provided to confirm nephron specificity and to give details on the posterior-anterior extent of ptger2a/4a expression (for example sections and co-stains with nephric markers). Further, studies should be performed to determine the critical time-window of prostaglandin responsiveness.*

We revised [Figure 4---figure supplement 4](#fig4s4){ref-type="fig"} to provide details of the anterior-posterior domain of *ptger2a* and *ptger4a* expression in the intermediate mesoderm with respect to the somites. Transcripts for each gene are initially detected in putative renal progenitors situated adjacent to somites 5 through 10 at the 12 ss stage, and as somitogenesis progresses they are both detected in a domain situated adjacent to somites 5 through 13 until approximately the 24 ss.

We did perform exhaustive testing of various *ptger2a/4a* probes for fluorescent WISH detection but were not able to determine the appropriate conditions for successful fluorescent labeling, which would have facilitated the most precise co-localization studies and confocal imaging. However, using standard WISH we were able to validate that *ptger2a* and *ptger4a* transcripts are expressed in the stripes of pronephros progenitors within the intermediate mesoderm due to their colocalization with *cadherin-17 (cdh17)* transcripts ([Figure 4---figure supplement 4C](#fig4s4){ref-type="fig"}).

*Reviewer \#2:*

*\[...\] 1) The authors over-simplify prostaglandin synthesis and signaling pathways, applying terminology and biological function relevant to PGE2 under the broad headline of \"prostaglandins\". This occurs as early as [Figure 1](#fig1){ref-type="fig"}, where they identify PGD2, PGA2, PGB2, and PGJ2 in the screen, which are known to stimulate thromboxane receptors (PGA2, B2) and PPARg (PGJ2), yet follow PGE2 (not a hit) and its relevant machinery. Similarly, Ptges is the enzyme for prostaglandin E2 synthesis (hence the \"e\" in its name, not general secondary processing), and Ptgers are the receptors for PGE2, not all of the PGs. While PTGS inhibition (Cox enzymes), could indeed broadly impact PG synthesis, the rest is quite specific to PGE2 and should not be generalized in the text, particularly when the screen hit several other potential modifiers as relevant to kidney biogenesis. This is not to say the data for PGE2 modification is wrong, it is just over generalized to \"prostaglandins\" and as such could cause issues for future investigations.*

We provided the simplified prostaglandin synthesis and signaling pathway in [Figure 1](#fig1){ref-type="fig"}, focusing on PGE~2~ relevant molecules, as an example to help orient readers. The accompanying text for this section was partly incorrect due to poor editing, and has now been revised for accuracy.

In the revision, we have endeavored to be more specific throughout. For example, the Abstract has been modified to articulate more precisely the manipulations and phenotypes. The Introduction has been edited to provide a better description of prostanoid production and to clearly designate that [Figure 1E](#fig1){ref-type="fig"} is an example of PGE~2~. Throughout the results, we revised our language to be specific when discussing PGE~2~, particular enzymes and receptors.

*2) Given the independent signaling cascades associated with PGB2 and PGE2, it is surprising that exposure to both enzymes elicited the same biological effect.*

We agree. However, it has been shown that different prostaglandins after certain thresholds of concentrations will freely interact with other prostaglandin receptors (Kiriyama et al., 1997, Tootle, 2013). This may explain why other prostaglandin compounds, such as PGB~2~, were capable of eliciting a similar effect as PGE~2~. One interpretation of the dosage-sensitive segment phenotypes is that they are related to this phenomenon. However, further studies are needed to truly distinguish specific effects of particular prostaglandins, such as by testing loss of function of particular prostaglandin synthases and the appropriate prostaglandin receptors during pronephros development.

*While receptor modulation is examined for 2 of the 4 PGE2 receptors, similar studies should be done in the context of exogenous PGE2 and PGB2 addition, as well as with the thromboxane receptors to confirm that addition of exogenous levels of each prostanoid doesn\'t cause errant signaling.*

We performed the experiments to test how addition of PGE~2~ affected the nephron phenotype in ptger2a and ptger4a deficient zebrafish (new [Figure 4---figure supplement 8](#fig4s8){ref-type="fig"}). Addition of PGE~2~ did not alter either the phenotype of ptger2a or ptger4a knockdowns, where we observed similar DE expansions and DL reductions as DMSO treated controls (new [Figure 4---figure supplement 8A, B](#fig4s8){ref-type="fig"}). This was confirmed by absolute segment length measurements and statistical analysis (new [Figure 4---figure supplement 8C](#fig4s8){ref-type="fig"}). While examination of thromboxane receptors would be another interesting area to explore, we believe it is beyond the scope of the present work.

*3) The doses utilized for dmPGE2 and Indomethacin are substantially higher than that found in other zebrafish or mouse papers, and well above physiological concentrations in humans. While the embryos appear grossly normal in whole mount images, it is important to document that alterations in kidney associated expression patterns are not simply due to gross morphological development issues or off target effects. Assessment of vascular markers by in situ or with a reporter line (Grosser et al) should be a quick way to test toxicity; receptor blocking analysis should confirm specificity.*

We assessed surrounding tissues following PG agonist (dmPGE~2,~ 100 µM) and PG antagonist (indomethacin, 30 µM) exposure by whole mount in situ hybridization, and also examined vascular integrity at later stages. We did not observe differences *flk1* or *gata1* transcript expression at 24 hpf in embryos exposed to DMSO, dmPGE~2~ or indomethacin between 4 hpf and 24 hpf, indicating normal vascular and primitive blood development, respectively (new [Figure 2---figure supplement 4A, B](#fig2s4){ref-type="fig"}). This is consistent with a published study that reported effects of indomethacin at 40 µM, but normal development of the vasculature following indomethacin treatment at 25 µM (Cha, et al., 2005). We also performed o-dianisidine (benzidene) staining in embryos treated with DMSO, dmPGE~2~ or indomethacin between 4 hpf and 24 hpf, which labels hemoglobinized erythrocytes and provides a sensitive assessment of defects in circulation or vascular integrity that can be undetected when using only live imaging with stereomicroscopy. With o-dianisidine staining, we observed that the drug treated embryos had equivalent vascular integrity compared to wild-type control embryos through the 48-55 hpf stage, such that we did not observe blockages or hematomas (e.g. bleeding, blood pooling) (new [Figure 2---figure supplement 4C](#fig2s4){ref-type="fig"}).

*4) While the overall conclusions seem well supported by the data shown, to make the paper more accessible to a general audience, the authors should use a more precise way to quantify the alterations in expression observed, or at least confirm the relevant ones, using ImageJ and/or a reporter line. The assays are currently very observational (with straight bars correlated with expression drawn on curvy embryos) and it is unclear how definitive statements like \"50% reduction\" are made when no quantification is shown.*

To make the paper more accessible, we now provide absolute segment length values in addition to our evaluation of segment domains relative to the somite number. We measured segment lengths in microns for the pertinent segments that change in drug treatments, morphants, and mutants using Nikon Software.

*Reviewer \#3:*

*\[...\]Whereas the proposed conclusions are significant and would be of interest to the developmental biology and renal research communities, they are not sufficiently supported by the presented data. Addressing the following questions and concerns would significantly strengthen the manuscript and make it suitable for publication.*

*One of the major concerns about the current manuscript is that there are many quantifications presented but without sufficient experimental detail to evaluate their statistical or biological significance. For several experiments (e.g. treatment of antagonists), there is insufficient experimental detail to evaluate the results and their interpretation. The quantifications of the phenotypes (reduction or expansion) of segments in various experimental regimens is given throughout the manuscript as% of embryos with altered expression (expanded or reduced). This shows that the fraction of affected embryos increases in a dose dependent manner but does not address whether the expressivity (degree of reduction or expansion) of the phenotype is also dose dependent. This is important given the overall conclusion that prostaglandins regulate segment patterning.*

Within [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"} -- different colored bars represent the degree of expansion or reduction as indicated by the legend and suggest that indeed, as prostaglandin concentration is increased there is an expansion of the PST up to 6 somites in domain length from that of the WT state of 3 corresponding somites. Additionally, we performed measurements of domain lengths of segments throughout the revised manuscript, which we believe provides the most clear description of the segment phenotypes.

*Were the measurements carried in a blinded fashion?*

*The number of embryos in individual experiments showing% of phenotype should be provided.*

All experiments showing% phenotype consisted of a minimum of at least 15 embryos per group in triplicate, which we have notated in the figure legends for the most complex data sets.

*For Indomethacin treated embryos, the authors conclude that they \"developed a 50% larger DE segment domain and a 20% smaller DL segment domain\" referring to [Figure 3](#fig3){ref-type="fig"} and its supplement. It is not clear where the data are presented on which this conclusion has been reached given that [Figure 3](#fig3){ref-type="fig"} shows fractions of affected embryos and not dimensions of pronephric segments in control and treated embryos. Such conclusions need to be supported by clearly presented morphometric data, with the method of measurement clearly described, as well as the numbers of analyzed embryos.*

In the revision we now provide absolute length measurements for all nephron segment phenotypes (Please see [Figure 2B](#fig2){ref-type="fig"}; [Figure 2---figure supplement 2E, F](#fig2s2){ref-type="fig"}; [Figure 3B, C](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1E, F](#fig3s1){ref-type="fig"}; [Figure 4---figure supplement 9](#fig4s9){ref-type="fig"}). Data involving phenotype penetrance and dosage responses have been moved to supplemental figures. We provide n values in either the graph or legend for all quantitations.

*The authors conclude that the changes in the dimensions of the pronephros proximo-distal segments represent the specific effects of prostaglandin signaling. However, the possibility of broader effects of prostaglandin signaling on embryonic dimensions and thus indirectly on pronephros is not sufficiently addressed. In the Methods the authors state \"Gene domains were measured with respect to somite boundaries to assess pattern formation\". However, the somitic staining that should provide such a reference is not clear in most of the figures. Given that earlier reports implicated prostaglandin signaling in morphogenetic movements of gastrulation (Gasser et al., PNAS, 2002; Cha et al., Genes & Dev, 2006; Speirs et al., Development, 2011), this needs to be carefully analyzed. Anteroposterior dimensions of the treated embryos should be measured as well as the relative size of pronephric segments to the neighboring somites for a reviewer/reader to evaluate.*

At the dosages for chemical treatments and various knockdowns, we did not observe noticeable morphological changes. To actually document this and provide quantification as well, we performed measurements to acquire absolute values in microns using Nikon Software for the pronephric domain (where the PCT begins and the DL ends), as well as for the anterior posterior axis of the embryos which we have denoted as \"tip to tail\" for dmPgE2, indomethacin, and 1% DMSO treated embryos. In both cases, we found no statistical differences between the groups (new [Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). These data support the conclusion that the segment domains changes are not simply a product of embryo dimension changes, but rather a modulation of segment specific identities.

*In experiments in which PG signaling was inhibited with various agents, it is not clear at what developmental stages was this done? Given the previous work implicating PG signaling in gastrulation movements the timing of the treatment is important. It would be also of interest to identify when during embryogenesis PG signaling is required for segment patterning and when it can affect it.*

We have revised the manuscript to ensure that the time window for chemical treatments was made more apparent in the results rather than having this stated in the methods. Next, we agreed that the perturbation of the prostaglandin pathway at later time windows was critical to assess. To address this, we treated embryos with dmPgE2, indomethacin, and 1% DMSO between the 12 ss to 24 hpf. In all cases, we observed that these treatments phenocopied their corresponding treatments from 4 hpf to 24 hpf (new [Figure 5](#fig5){ref-type="fig"}). Additionally, we treated embryos with the ptger2a antagonists (AH6809 and PF04418948) from the 12ss to 24hpf and saw a similar increase of the DE and decrease of the DL as seen in treatments from 4hpf to 24hpf (new [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).

*Injection into 1 cell stage embryos of translation and splicing morpholinos targeting ptgs1 (cox1) and ptgs2a (cox2) enzymes is reported to affect pronephros patterning. However, it has been previously reported that ptgs1 morpholino injections caused severe epiboly defects (Gasser et al., 2002). In this work the morpholino experiments are insufficiently described. There is no information on the dosage of morpholinos per embryos (only stock concentration is given in methods), no dose response, no experiments describing the degree of loss of function. Yet, the authors conclude \"these data indicate that endogenous levels of prostaglandins are critical for specification of the DE and DL segments\". This conclusion is given before dmPGE2 rescue experiments are described.*

*Similar lack of detail and controls is a concern for the experiments in which two genes encoding the prostaglandin receptors, ptger2a and ptger4a are targeted using morpholinos. There are no data on the effectiveness of these reagents to downregulate expression of these genes and encoded proteins, or to lower the levels of prostaglandins. Since in recent years, significant concerns have been raised about the specificity of morpholinos (e.g. Kok et al., Dev Cell, 2015), the sparse details and controls for the experiments presented raise concerns.*

We have modified our Methods and figures/figure legends to more clearly describe our morpholino related experiments. While most of morpholinos described in the present work have been used in a number of other published studies (Grosser et al., 2002, Cha et al., 2006, North et al., 2008, Nissim et al., 2014), we do recognize the need for morpholino work to be verified. Indeed, part of our rationale for extensive parallel studies with chemical genetics and use of multiple knockdown reagents was to study these factors with independent tools. Unfortunately, we are unable at the present time to assess the consequential protein levels of the genes targeted by morpholinos that interact with 5'UTR or translational start site due to the lack of appropriate specific antibodies. However, in the revision, we provide a thorough transcriptional analysis to document the effects of splice morpholinos used for knockdown of *ptgs1, ptgs2a, ptger2a,* and *ptger4a* using RT-PCR (new [Figure 4---figure supplement 10](#fig4s10){ref-type="fig"}). In all cases, we were able to confirm that incorrect splicing occurred as a product of each splice morpholino or combination (new [Figure 4---figure supplement 10](#fig4s10){ref-type="fig"}). In fact, for each gene, we found that the morpholino microinjection eliminated the presence of wild-type transcripts. In the case of *ptger2a* and *ptger4a*, we needed to obtained splice targeting morpholinos and we have validated their phenotypic effects on the pronephros (new [Figure 4---figure supplement 10, E, F](#fig4s10){ref-type="fig"}).

*In epistasis experiments presented in [Figure 6A, B](#fig6){ref-type="fig"} it would be important to see the effect of SC-580 alone.*

We provide data on the effect of the selective Cox1 inhibitor in [Figure 4](#fig4){ref-type="fig"}, with the absolute segment length changes documented in [Figure 4---figure supplement 9](#fig4s9){ref-type="fig"}. In [Figure 6A](#fig6){ref-type="fig"} we provide a representative image to remind readers of the DE phenotype from exposure to this compound.

*From the perspective of the model of PG -- irx3b pathway proposed in [Figure 7A](#fig7){ref-type="fig"}, the effect of dmPGE2 treatment that affect PST and DL but do not affect DE are confusing.*

The working models depict the effects of PGE~2~ on segment size, where (A) PGE~2~ biosynthesis is required to restrict the DE by inhibiting the domain of *irx3b* expression and to promote the DL, and (B) PGE~2~ applied exogenous is capable of positively modulating the size PST segment by promoting *sim1a* expression, and meanwhile inhibiting the DL. In the case of (B), the DE segment develops at a normal size but the position is altered along the anterior-posterior axis, likely due to the PST expansion and the shifted domain of *irx3b* expression, and thus we thought that drawing an arrow between PGE~2~ and the DE in this case would be misleading compared to the other arrows and phenotypes because the DE segment size in this case is normal. We edited the figure legend to remind readers that we correlated a change in the *irx3b* domain to the shift in the DE location, and that changes in the *mecom* expression domain correlate with the DL reduction in both (A) and (B).

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

*\[...\] The manuscript has been substantially improved and all reviewers\' comments have been addressed well. The additional experimental data help to strengthen and support the findings, and the writing is now clear and precise. Overall, this is a very interesting study and should be of wide interest.*

*One concern remains: the quantification has been improved but there was very little information about the statistical tests used for analysis of the data. t-tests are mentioned in the Materials and methods section, but these will not be suitable for analysis of some of the datasets, where there are multiple conditions and comparisons. Here, a test such as ANOVA, with appropriate post-test correction for multiple samples, would be preferred. Alternatively, the authors should clarify and justify the tests they have used. The tests that are used should be stated in each of the figure legends where appropriate, in addition to the statement in the Materials and methods.*

We have revised the Materials and methods as requested, and we have edited each figure legend to state which statistical analysis was used.

With regard to our statistical tests: In many figures, we utilized unpaired t-tests to compare nephron segment lengths between two samples. However, in cases of 3 or more samples, we now report the outcome of ANOVA tests rather than t-tests, as ANOVA is preferred for comparisons across multiple samples. We have now revised the following figures with ANOVA results: [Figure 2---figure supplement 3A, B](#fig2s3){ref-type="fig"}; [Figure 4---figure supplement 8C](#fig4s8){ref-type="fig"}; [Figure 4---figure supplement 10F](#fig4s10){ref-type="fig"}; [Figure 5C](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1B, C](#fig5s1){ref-type="fig"}; and [Figure 6B](#fig6){ref-type="fig"}. These revisions provide a more appropriate statistical analysis for numerous aspects of the work.

In contrast, however, in the graphs reporting the percentage phenotype following drug or morpholino treatments, we focused on the key comparison of each individual phenotype to the corresponding wild-type control. For this, we utilized unpaired t-tests, and have revised the figure legends to clearly indicate our analysis. While it might be interesting to look across groups in some cases, our primary goal of these statistical analyses was to determine whether PGE~2~ treatment or alterations of endogenous prostaglandin biosynthesis significantly altered nephron segments compared to wild-type control embryos, as opposed to delving into the cross-treatment comparisons.
